VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 16 (13-20 agosto / 2024)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

Dengue Vaccine TAK-003 Confirmed to be Safe, Effective

13 ago. A new meta-analysis published in the journal Vaccines confirmed that the dengue vaccine TAK-003 is highly effective, reducing disease cases by more than 50%, with lasting effects and an excellent safety profile.

TAK-003 is the first and only dengue vaccine approved by the European Medicines Agency. Authorized in December 2022, it is now available in Italy and other European countries.

The vaccine is designed as a 2-dose regimen administered 3 months apart for individuals aged 4 years and older, regardless of previous dengue exposure. However, official immunization recommendations across European Union countries are still being developed. What's more, available evidence on the clinical efficacy and safety of TAK-003 is inconsistent.

To address these gaps, investigators conducted a meta-analysis to evaluate the immunogenicity, efficacy, and safety of TAK-003 after administration of a single dose and the complete 2-dose schedule. By comprehensively assessing the vaccine's performance, the meta-analysis aimed to provide essential insights for optimizing the use of TAK-003 in dengue prevention.

Investigators examined and cross-referenced data from 19 studies examining the immunogenicity, efficacy, and safety of the live-attenuated, tetravalent dengue vaccine TAK-003 across all age groups. The combined data included over 20,000 participants followed for more than a year after final vaccination dose.

Five studies were conducted in the USA, 1 in the UK, and all others in Asian or Central and South American countries, where dengue fever is endemic.

The main outcome of immunogenicity was seroconversion and secondary outcomes focused on clinical efficacy and safety measured by serious adverse events (SAEs). All immunogenicity analyses were stratified by dengue's 4 distinct strains: DENV-1, DENV-2, and DENV-3, and DENV-4.

Overall, 2 doses of TAK-003 successfully induced the production of neutralizing antibodies against all 4 dengue serotypes in at least 90% of adults and children and adolescents, regardless of whether they were seronegative or seropositive at baseline.

A single dose of TAK-003 elicited a high-to-very-high immunogenic response against all 4 serotypes, as well. Seroconversion rates exceeded 90% in children and adolescents and remained high at 70% or more in adults. The lowest seroconversion rates (70-80%) were observed against DENV-3 and DENV-4 in adult participants who were seronegative.

Due to a limited adult study population, all vaccine efficacy results based on intention-to-treat analyses referred to children and adolescents. After completing the 2-dose regimen, the vaccine significantly reduced the risk of dengue disease caused by DENV-2 and DENV-1 by over 80% and 40%, respectively, in both seropositive and seronegative individuals (P < 001).

However, vaccine effectiveness against DENV-3 and DENV-4 varied based on serological status. While the vaccine significantly protected those who were seropositive (RR = .50 for DENV-3; RR = 0.3 for DENV-4; both P <.001), it offered no protection for seronegative children and adolescents (P >.20).

Further, 1 or 2 doses of TAK-003 demonstrated excellent safety profiles, with a frequency of SAEs that was comparable with those observed among the controls.

Based on their findings, investigators offered suggestions for vaccination guidance.

"The vaccine was able to reduce the overall rate of dengue fever by more than half in both seronegative and seropositive children/adolescents," they wrote. "Therefore, considering the results on safety, immunogenicity and efficacy following the administration of 2 vaccine doses, TAK-003 may certainly represent a central tool for the prevention of dengue fever among children and adolescents in highly endemic countries or within-country areas."

Although 2 doses of TAK-003 are typically recommended for travelers from non-endemic regions visiting dengue-prone areas, researchers also suggested that a single vaccine dose could be considered for populations in non-endemic countries experiencing high dengue outbreaks.

This suggestion is especially important given the increasing global threat of dengue virus, whose incidence reached a record high in 2024. Climate change has exacerbated this surge by expanding the vector of dengue-carrying Aedes mosquitoes. The Americas have been particularly affected, with more than 9.7 million cases reported between January and June of this year alone—double the total amount of all cases reported in 2023.

"Given the results in terms of safety, immunogenicity, and efficacy, the administration of 2 doses can undoubtedly be a key tool for dengue prevention," said Maria Elena Flacco, lead study author and director of the school of specialization in public health at the University of Ferrara, in a news release. "The currently available vaccine can therefore be very useful not only for populations in endemic areas but also for travelers from non-risk areas."

Going forward, investigators called for preferably independent studies to clarify the efficacy of TAK-003 for adults against serotypes 3 and 4 and the potential use of a single vaccine dose in non-endemic countries.

Fuente: Drug Topics. Disponible en https://acortar.link/IGyb9D

New RSV vaccine could prevent 5,000 infant hospitalisations

Aug 13. Study shows new RSV vaccine for pregnant women could prevent 5,000 hospitalisations and 15,000 emergency department attendances for infants.

The UK Health Security Agency and Joint Committee for Vaccination and Immunisation (JCVI) are highlighting the benefits the new Respiratory Syncytial Virus (RSV) vaccination programme is expected to bring following its introduction from September.

A recent detailed analysis[1] estimated that the new programme launching in England this autumn could typically prevent 5,000 hospitalisations and 15,000 emergency department attendances for infants.

The study bases its estimates on the assumption that uptake among pregnant women will be around 60%. It also estimated that the maternal programme could mean 70,000 fewer RSV illnesses in infants under 12 months, 20,000 fewer GP consultations and avoid more than 200 infants being admitted to intensive care units.

Despite infecting around 90% of children within the first 2 years of life, RSV is not something that many

people are aware of. It typically causes mild, cold-like symptoms. However, it can lead to severe lung infections like pneumonia and infant bronchiolitis and is a leading cause of infant mortality globally.

RSV illness is the main cause of winter pressures in children's hospitals each year leading to pressure on paediatric intensive care units, including cancelled operations. It accounts for approximately 20,000 hospitalisations in children under 1 and is responsible for 20 to 30 infant deaths a year in the UK.

The UKHSA continues to work rapidly with NHS colleagues to ensure an effective roll out of the two new programmes and will also monitor the impact of the programmes through its routine national surveillance.

Professor Dame Jenny Harries, Chief Executive of the UK Health Security Agency, said:

These two new RSV vaccine programmes - one for pregnant women and another for older adults as they turn 75 - offer huge opportunities to prevent severe illness in those most vulnerable to RSV, helping to protect lives as well as ease NHS winter pressures.

UKHSA has provided critical scientific information to evidence the benefits of a national RSV immunisation programme and so the rollout of the vaccine is a truly positive moment for the public's health. I urge all those eligible, to take up the offer when the programmes begin in September.

Dame Jenny Harries added:

Having the vaccine during every pregnancy is the best way to protect your baby against RSV, as the vaccine boosts your immune system to produce more antibodies against the virus, and these then pass through the placenta to help protect your baby from the day they are born. The vaccine reduces the risk of severe bronchiolitis by 70% in the first six months of life.

The RSV vaccine is the safest way to protect you and your baby. It has been approved by medicines regulators in the UK, Europe and the USA. Many thousands of women have had the vaccine in other countries, including more than 100,000 women in the USA.

Andrew Gwynne, Minister for Public Health and Prevention, said:

Maternal vaccinations are crucial to protect newborns from life-threatening illnesses like RSV.

Sadly my grandson caught RSV, just days after he was born. It led to weeks in intensive care and persistent, long-lasting health issues. I wouldn't wish that on any family. This new vaccine programme offers us an opportunity to prevent similar trauma, helping stop thousands of hospitalisations while saving precious lives.

I urge everyone eligible to get the vaccine. By doing so, you will provide protection from the first day of your baby's life and safeguard your child's future.

Steve Russell, NHS National Director for Vaccinations and Screening, said:

This is a vitally important study demonstrating the huge impact the RSV vaccine will have, reducing pressure on NHS services during the winter months but more importantly keeping infants out of hospital and saving lives.

The NHS will be rolling out the vaccine from 1 September and with RSV infecting around 90% of children in their first two years of life, we strongly encourage pregnant women who are 28 weeks pregnant or more to speak to their maternity team or GP about getting vaccinated - it could save your child's life. While those aged 75 to 79 should come forward as soon as they are invited by their GP.

In addition to the maternal vaccine programme, a free RSV vaccine will be offered to all those turning 75 years on or after 1 September, along with a one-off campaign for those already aged 75-79 years.

The same modelling – using enhanced surveillance of older adult admissions[2] – suggests that the first season of the older adult's catch-up programme could prevent around 2,500 hospital admissions, 15,000 GP visits and 60,000 RSV illnesses in adults in this age group.

Fuente: Gov.UK News. Disponible en https://acortar.link/PuDijn

In Biocen's manufacturing lines, the company's own medicines and those developed by others

Aug 14. On August 14, 1992, the historical leader of the Cuban Revolution, Commander-in-Chief Fidel Castro Ruz, founded the National Center of Biopreparations, as part of the Scientific Pole of western Havana.

Photo: Courtesy of BioCen

The upcoming start of production of the Cuban anti -pneumococcal vaccine, Quimi-Vio, the trivalent antileptospirosis vaccine, VAX-SPIRAL and the polysaccharide antityphoid Vi vaccine, VAX-TyVi, following the transfer of technology from the Finlay Vaccine Institute (IFV), are among the main tasks being carried out these days at the Parenterales plant of the National Center for Biopreparations (BioCen).

This was explained to Granma by Daniela Hormía Rodríguez, director of Parenterales of Biocen, who added that they will also receive the transfer for the production of the Quimi-Vio 11 valente vaccine, which is a product under development by the IFV, but which will be produced so that clinical trials can be carried out.

She specified that, as part of the manufacturing of the center's products, the production of Biomodulin-T and Biomodulin-T in 6R format was licensed in plant 2 of parenterals.

Just in the framework of the celebrations for the 32nd anniversary of the founding of Biocen -on August 14, 1992- by the historic leader of the Cuban Revolution, Commander-in-Chief Fidel Castro Ruz, as part of the Scientific Pole of western Havana, this center transforms and diversifies its functions.

BIOCEN BRAND PRODUCTS

According to Humberto Pérez de la Concepción, deputy director of the Center, the founding concept of this high-tech company was to provide a large-scale productive outlet for the biotechnology products developed by the research, innovation and development (R&D&I) companies of the Western Scientific Pole.

However, over time, Biocen has also become not only a producer, but also a developer of products. An example of this is Biomodulin-T, a biological immunomodulator of natural origin, not hemoderivative, composed of specific fractions of the bovine thymus, with the aim of restoring the immunological deficit, he explained.

Pérez de la Concepción told Granma that the company's own products also include anti-anemia and nutritional supplements (liquids and tablets) of natural origin registered under the Trofin brand -Trofin/ Biotrofer, Neotrofin, Neotrofin C F (also composed of vitamin C and folic acid) and Trofinvital- which contain a

hydrolyzed bovine blood, bee honey and propolis, which guarantee their easy absorption by the organism.

The company's own products include dehydrated culture media, reagents and supplements, ready-to-use liquid media for aerobic blood cultures, and the nutritional supplements of the PorMás line, the result of an alliance between the Institute of Sports Medicine, CubaDeportes S.A. and the center.

They are also honored with the development of the btv virus transport medium, a cell culture medium for the transport of nasopharyngeal and oropharyngeal clinical samples suspected of containing the SARS-CoV-2 virus.

Photo: Dunia Álvarez

SARS-CoV-2, which during the COVID-19 pandemic ensured technological sovereignty, active maintenance of the national epidemiological surveillance system, and confirmation of the diagnosis of the disease.

The National Center for Biopreparations is also the only one in the country to have a full-cycle platform for allergy vaccines (Research-Development-Production-Marketing and Follow-up), making available to patients three therapeutic vaccines: Valergen BT, Valergen ds and Valergen DP (injectable and sublingual), intended for the treatment of patients with allergic sensitization to house dust mite allergens.

Regarding the manufacture of these products for the National Health System, the Deputy Director of Biocen pointed out that this is the first commitment, so they are working against a controlled demand, especially for those products that are part of the basic drug list (Biomodulin-T and the Trofin family).

He stated that they follow up on production levels, work on the quality of the batches and their distribution nationwide.

Fuente: Granma. Disponible en https://acortar.link/N2Fx7u

Conceden patente a vacuna del coronavirus desarrollada en Medellín

15 ago. La oficina de Patentes y Marcas de Estados Unidos concedió la patente al desarrollo de la vacuna universal del coronavirus desarrollada en Medellín.



Este desarrollo contó con la participación de 12 científicos y profesionales de distintas partes del país, quienes trabajaron en su investigación y desarrollo en la capital antioqueña. La vacuna se podrá producir en la nueva planta de VaxThera en el Oriente de Antioquia.

En medio del caos generado por la pandemia por COVID-19, 12 científicos de diferentes regiones de Colombia comenzaron a idear el desarrollo de una vacuna contra el virus, 3 años después de distintas fases de investigación y desarrollo en un laboratorio de

Medellín, lograron desarrollar una vacuna universal contra el coronavirus, es decir, la vacuna puede atacar el virus en sus distintas variantes.

En este laboratorio de Medellín fueron instalados equipos de última tecnología, incluso, dispositivos de los cuales en el mundo solo hay 5 ejemplares y que permiten el avance y desarrollo de la investigación.

Incluso, se usaron modelos de inteligencia artificial para su investigación. Tras lograr superar las pruebas y obtener esta patente, la vacuna podrá producirse en la planta de VaxThera inaugurada en mayo de este año en el oriente antioqueño y que avanza en los ajustes finales para entrar en funcionamiento en los próximos meses.

En Colombia no se producen vacunas desde 1998, ahora, no solo está la posibilidad de la planta para producirlas, sino que se ha desarrollado una vacuna única en el mundo.

Esta patente es un reconocimiento y un hito a la investigación en nuestro país, pues desde Antioquia se podrá atender en caso de ser necesaria la producción de vacunas en escenarios como el de la pandemia sin necesidad de importarlos, así como aportar a las investigaciones mundiales en el desarrollo de soluciones médicas.

Fuente: TeleMEDELLÍN. Disponible en https://acortar.link/RvIVHl

Crean fármaco contra COVID con 'células asesinas' sintéticas



Aug 16. Un equipo de investigación japonés formado por científicos de la Universidad de Kioto y la Universidad de Salud Fujita ha desarrollado un nuevo fármaco contra COVID-19 basado en células inmunitarias sintetizadas partir de células madre.

Este equipo tiene previsto realizar un ensayo clínico dentro de tres años en pacientes inmunodeprimidos a causa de la quimioterapia y que sufren síntomas graves de COVID-19, según explicaron los científicos.

La Universidad de Kioto ha presentado una solicitud de registro de patente antes de desarrollar el medicamento a gran escala.

"Aunque el COVID-19 se ha convertido en una enfermedad menos peligrosa, sigue siendo aterradora para algunos pacientes", afirmó el jefe del equipo, Hiroshi Kawamoto, director del Instituto de Ciencias Médicas y de la Vida de la Universidad de Kioto, en un comunicado de esta institución.

El nuevo tratamiento se basa en linfocitos T citotóxicos, también conocidos como 'células asesinas' por su capacidad de destruir otras células infectadas por microorganismos, y en este caso creadas de manera artificial por el equipo de investigación a partir de células madre pluripotentes inducidas.

Efectividad comprobada

Las células, desarrolladas para reducir el riesgo de rechazo por parte de los pacientes, tienen genes con funciones de 'sensores' para detectar las proteínas exclusivas del nuevo coronavirus.

El grupo de científicos comprobó su efectividad tras cultivar las células sintéticas junto a las infectadas con el nuevo coronavirus, de las cuales fueron eliminadas alrededor del 90 % tras doce horas.

El equipo de investigación también incluye miembros de la Universidad de Osaka y del Centro Nacional de Salud y Desarrollo Infantil japonés, quienes tienen previsto realizar pruebas con ratones para determinar la seguridad del tratamiento y consideran esta nueva tecnología puede ser útil para combatir otras enfermedades víricas letales.

En el ensayo clínico, las células desarrolladas artificialmente serán administradas por vía intravenosa, comentó Kawamoto, quien añadió que el riesgo de efectos secundarios graves, como los que se observan en las terapias inmunológicas, es bajo.

Fuente: DW. Disponible en https://acortar.link/cP3VyL

Vacuna '2x1' de Pfizer contra COVID-19 y gripe falla en ensayo final

16 ago. Una vacuna combinada contra COVID-19 y gripe desarrollada por Pfizer y BioNTech no logró uno de sus objetivos en un ensayo de fase final, una decepción para las empresas que intentan hacer un mayor uso de la tecnología que tuvo éxito durante la pandemia.

La vacuna no demostró ser al menos tan eficaz como una inyección estándar para generar una respuesta inmunitaria contra la cepa de la gripe B, informaron las empresas en un comunicado este 16 de agosto.

La inyección funcionó mejor con la gripe A y la COVID-19. Pfizer aclaró que las dos empresas están estudiando ajustes a la vacuna que podrían aumentar su eficacia contra la gripe B.

El fallo en la fase 3 de los ensayos de la vacuna combinada contra gripe y COVID-19 de Pfizer-BioNTech puede poner a los socios en desventaja frente a Moderna, que tuvo éxito en la fase 3 en junio. Vemos las vacunas combinadas como una importante herramienta de marketing y comercialización para que las tres empresas impulsen la adopción de las vacunas contra enfermedades respiratorias, ayudándolas a competir con empresas como GSK y Sanofi.

Una combinación reelaborada puede retrasar a Pfizer-BioNTech al menos dos años y necesitaría un nuevo ensayo de fase 3, señaló Sam Fazeli, analista de Bloomberg.

¿Qué problemas económicos y legales ha enfrentado Pfizer?

Los resultados complican los esfuerzos de Pfizer por compensar la caída de las ventas de su vacuna COVID, que se redujeron 70 por ciento en 2023. Moderna, fabricante de una vacuna rival contra COVID-19, informó en junio de resultados positivos en la última fase de una vacuna combinada contra el virus SARS-CoV-2 y la gripe.

El estudio de Pfizer, en el que participaron más de 8 mil adultos, comparó la vacuna combinada con una vacuna contra la gripe aprobada. La empresa también reveló los resultados de un ensayo más pequeño y de

fase inicial en el que una vacuna combinada de segunda generación produjo una respuesta inmunitaria suficiente contra las cepas A y B de la gripe.

Esta no ha sido la única mala noticia para Pfizer durante este mes: Un exempleado, Amit Dagar, fue condenado por fraude de valores y conspiración y sentenciado a nueve meses de prisión por ganar más de 200 mil dólares comerciando con información confidencial antes de un anuncio clave sobre Paxlovid, tratamiento de la farmacéutica contra la COVID-19.

Fuente: EL FINANCIERO. Disponible en https://acortar.link/EG4HyT

Updated COVID-19 vaccines could be ready next week

Aug 17. The U.S. Food and Drug Administration is set to approve the latest COVID-19 vaccines for the ongoing pandemic. CNN reports two sources familiar with the matter say approval could come before the end of next week.

The FDA will likely approve the updated mRNA vaccines from Pfizer/BioNTech and Moderna that target one of the latest strains of COVID-19 known as KP.2. Novavax's updated shot targets another strain known as JN.1.

If approved next week, it would come much earlier than last year, when updated vaccines were approved by the FDA on September 11.

The new vaccines come as a surge of COVID-19 cases have been reported in recent weeks across the country. Although detailed monitoring of cases is no longer conducted, an analysis of wastewater levels was found to be at its highest rate during the summer months since 2022.

ER visits, hospitalizations and deaths are also on the rise, with four times the rate of hospitalizations in July compared to May.

Pfizer and Moderna tell CNN they already have plenty of the updated vaccines ready to go once they receive approval, and will ship them out immediately following approval, and available in pharmacies and health care centers in a matter of days after approval.

The World Health Organization declared the Coronavirus Pandemic started in March of 2020 and has not yet ended, as cases continue to spread across every populated continent year-round, unlike more seasonsal epidemics like the flu.

Fuente: CBS Iowa´s News. Disponible en https://acortar.link/iBfr8A

Laboratorio CDV inaugura en Argentina una planta de vacunas contra la brucelosis

17 ago. Requirió una inversión de 4 millones de dólares y cuenta con capacidad para producir 10 millones de dosis de vacunas antibrucélicas en su primera fase. Este avance refuerza la expansión de la compañía hacia mercados internacionales clave.

La brucelosis es una enfermedad bacteriana que afecta principalmente al ganado y perros. Las personas la

contraen por contacto con animales infectados o productos contaminados, especialmente leche no pasteurizada.

El Laboratorio CDV anunció la apertura de su nueva planta de elaboración exclusiva de vacunas contra la brucelosis, ubicada en la Planta 1 en el Parque Industrial de Pilar. Con una inversión total de cuatro millones de dólares en obra civil, equipamiento de servicios de planta y equipos de producción.

Esta nueva área exclusiva de producción para vacunas contra la brucelosis, es parte de un paquete de grandes inversiones que se encuentra realizando la empresa en la Argentina.

Las modernas instalaciones de la planta de elaboración de vacunas contra la brucelosis comprenden dos áreas de producción completamente independientes para la elaboración de los dos diferentes tipos de Brucella, cepa 19 y cepa RB51: un laboratorio de control de calidad y un área de servicios.

“El inicio de la producción comenzó en julio de 2024 y proyectamos que nuestros productos estén disponibles a partir de septiembre de 2024. Con esta nueva línea de producción, estimamos seguir creciendo y alcanzar un 35% de participación en el mercado. Del total producido, el 70% se destinará al comercio internacional, principalmente a países de Latinoamérica, Asia y Medio Oriente. Este es un enorme paso para el Laboratorio CDV en nuestra misión de expandirnos a nuevos mercados y satisfacer la demanda de productos de calidad, en pos de la prevención y sanidad animal”, afirmó Juan Roô – gerente general de Laboratorio CDV.

El gerente General de la firma aseguró: “La decisión de avanzar con esta nueva planta responde a la necesidad de aumentar la capacidad productiva debido al crecimiento de los pedidos de vacunas de acuicultura -hasta el momento se elaboraban, en forma alternada, en la misma planta que las vacunas de Brucelosis-; la demanda de Brucelosis Cepa 19; y la obtención de registros en el exterior de Brucella RB51. En Argentina, el Servicio Nacional de Sanidad y Calidad Agroalimentaria (SENASA) lidera un plan de control y erradicación de la brucelosis”, finalizó Roô.

El Laboratorio CDV está inmerso en un ambicioso proyecto de expansión hacia nuevos mercados internacionales como parte fundamental de su estrategia de negocio y crecimiento. Con el objetivo de ampliar su alcance y consolidar su presencia a nivel global, CDV busca detectar nuevas oportunidades, fomentar colaboraciones internacionales y poner a disposición sus productos con tecnología innovadora y altamente competitiva en un contexto internacional, demostrando su firme compromiso con la prevención de la sanidad animal.

El Laboratorio CDV aspira a ser la primera empresa en Latinoamérica en obtener la certificación bajo las normas PIC/S (*Pharmaceutical Inspection Co-operation Scheme*), un proceso que inició en 2019. Las Normas PIC/S (*Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme*) son un conjunto de directrices internacionales diseñadas para armonizar las prácticas de inspección y garantizar la calidad de los productos farmacéuticos. Estas normas son desarrolladas y mantenidas por la Convención de Inspección Farmacéutica y el Esquema de Cooperación de Inspección Farmacéutica, una

organización internacional que reúne a las autoridades regulatorias de medicamentos de varios países y regiones.

Para lograrlo, además de su nueva planta de vacunas contra la brucelosis, la recientemente galardonada como Mejor empresa en Sanidad Animal de Latinoamérica 2023 (Premio Animal Health Awards), ha realizado una inversión inicial de 60 millones de dólares en una tercera planta, de elaboración de vacunas veterinarias, diseñada conforme a los estándares internacionales de World Class Manufacturing. Dicha obra, que espera abrir sus puertas para el primer semestre de 2025, no solo cumplirá con estos rigurosos requisitos, sino que también adoptará un enfoque de «industria verde» que optimizará los recursos y mejorará la eficiencia de producción. La planta integrará diseño, tecnología e innovación en tres áreas clave: construcción, equipamiento y gestión eficiente de recursos naturales.

La firma, presente en nuestro país desde hace casi 40 años, continúa invirtiendo en mejoras de instalaciones, nuevas tecnologías e investigación para continuar brindando productos de excelencia en el sector veterinario, abastecer el mercado argentino y ser referentes reconocidos en los mercados internacionales.

Brucelosis, una zoonosis de amenaza mundial

La brucelosis es una enfermedad bacteriana que afecta principalmente al ganado y perros. Las personas la contraen por contacto con animales infectados o productos contaminados, especialmente leche no pasteurizada. Según la OMS, es una de las zoonosis más extendidas, con graves consecuencias para la salud pública en áreas endémicas. La expansión de la industria animal y la urbanización aumentan el riesgo. Aunque rara vez se transmite entre personas, representa un peligro ocupacional para los trabajadores ganaderos. La vacunación y pruebas serológicas son claves para la prevención. También son cruciales la pasteurización de la leche, evitar productos lácteos no pasteurizados, y medidas de higiene en la manipulación de animales y sus productos.

Los síntomas de la brucelosis en humanos son similares a los de la gripe, incluyendo fiebre, debilidad, malestar y pérdida de peso, aunque pueden presentarse de forma atípica y variar en severidad. El periodo de incubación puede variar de una semana a dos meses, generalmente entre dos y cuatro semanas. La identificación y tratamiento de la enfermedad pueden ser complicados debido a la presentación leve de los síntomas en algunos pacientes.

En la actualidad se utiliza el Sistema Nacional de Vigilancia de la Salud (SNVS), para la vigilancia y la notificación de los casos de brucelosis humana. Según los últimos datos informados, para el año 2022 se notificaron 777 casos, de los cuales se confirmaron como brucelosis 104, tal como muestra la siguiente tabla.

Mediante dicho plan se inmunizan anualmente todas las terneras entre los 3 y los 8 meses de edad con vacuna antibrucélica cepa 19. Dicho plan ha logrado reducir la prevalencia al 0,8% animal según los últimos datos del SENASA. En la región, varios países han vuelto a incorporar la cepa 19 dentro de sus calendarios sanitarios, el último caso es el de Costa Rica, que el año pasado ha adquirido más de 100 mil dosis de

vacuna CDVac Brucelosis cepa 19 elaborada por Laboratorio CDV para comenzar un nuevo plan de control de la enfermedad en el país.

Acerca de Laboratorio CDV

CDV es un laboratorio argentino líder, especializado en la elaboración de biológicos para la prevención de enfermedades que afectan a los rodeos bovinos y ovinos del país, con más de 35 años de trayectoria en la Argentina. Su línea de productos y servicios orientados a la prevención es la más completa del mercado, compuesta por vacunas virales y bacterianas, vacuna Antiaftosa, reactivos y servicio de diagnóstico. Pionero en el desarrollo de la vacuna para el control de Diarrea Viral Bovina con cepas nacionales y la incorporación de adyuvante en doble emulsión para la mejora de la respuesta inmune. También es uno de los primeros centros de diagnóstico de enfermedades veterinarias y miembro de la Red de Laboratorios de SENASA. Desde el 2002 innova en la producción de biológicos para la acuicultura y es el único laboratorio que cuenta además con un Laboratorio de Diagnóstico propio, que le ha permitido conocer la problemática de las principales enfermedades que afectan a los rodeos a nivel productivo y así elaborar productos que se ajusten a la casuística de la región. En enero de 2020, la revista británica Animal Pharm distinguió al laboratorio CDV como la “Mejor empresa del Sector Veterinario en Latinoamérica del 2019”. CDV exporta sus productos a más de 15 países. En el año 2023 el laboratorio, por segunda vez, fue reconocido como Mejor Empresa de Latinoamérica en los premios Animal Health Awards.

Cuenta con dos modernas plantas de producción de vacunas y una tercera en desarrollo ubicadas en el Parque Industrial Pilar, provincia de Buenos Aires:

Planta 1: desde el año 2003 producimos vacunas para la prevención de enfermedades reproductivas, respiratorias, clostridiales, queratoconjuntivitis, complejos entéricos neonatales y preventivos de importantes enfermedades zoonóticas como Brucelosis, Rabia, Carbunclo y Leptospirosis. También elaboramos reactivos de diagnóstico para la detección de Tuberculosis y Brucelosis y vacunas para prevenir enfermedades en las aves y salmónidos. En el mismo predio, se encuentra el Laboratorio de Diagnóstico, perteneciente a la red del SENASA. Tiene una capacidad total de producción anual de 150 millones de dosis: 85 millones de dosis para vacunas de bovinos y, el resto, para salmónidos y aves.

Planta 2: se producen exclusivamente vacunas antiaftosa desde el año 2018. Esta Planta cuenta con equipamiento de última generación y con un alto grado de automatización de sistemas para garantizar el cumplimiento de los estándares de calidad y bioseguridad más exigentes a nivel mundial. La capacidad productiva actual varía entre 2.5 y 5.0 millones de dosis mensuales, dependiendo del formato de vacuna (tetravalente y bivalente respectivamente).

Planta 3: actualmente está en construcción y se estima que esté operativa hacia fines del 2024. Ampliará la capacidad productiva de Planta 1 y se podrán elaborar productos para la sanidad animal y la prevención de enfermedades en nuevas especies: vacunas para mascotas, animales de compañía y cerdos. La capacidad productiva total proyectada alcanzará, junto a la producción de planta 1, los 280 millones de dosis, de las cuales 190 millones corresponden a vacunas para bovinos (destinadas al mercado interno y a la exportación) y el resto corresponden a vacunas para salmónidos y otras especies como cerdos y animales de compañía.

Fuente: Valor Agregado. Disponible en https://acortar.link/73H1pO

India working on developing vaccine for dengue

Aug 18. While development of a dengue vaccine has been perennially in the making, the recent launch of the third phase of clinical trials of dengue vaccine in India by ICMR with Panacea Biotec, has raised hopes over the availability of a dengue vaccine to the general public in the next few years.

With cases of dengue continuing to surge every year in Telangana and across the country, several vaccine manufacturers from India and abroad are in a race to develop and launch a robust dengue vaccine that could potentially reduce the disease burden and strain on public health institutions in the country.

While development of a dengue vaccine has been perennially in the making, the recent launch of the third phase of clinical trials of an indigenously developed dengue vaccine in India by Indian Council of Medical Research (ICMR), in collaboration with Panacea Biotec, has raised hopes over the availability of a dengue vaccine to the general public in the next few years.

Being considered by many as a landmark trial to evaluate efficacy of indigenous tetravalent dengue vaccine, DengiAll (brand name), the tetravalent dengue vaccine strain was originally developed by National Institutes of Health (NIH), USA and Panacea Biotec, which received the strain, is at the most advanced stage of development.

The phase I and II of this vaccine was completed in 2018-19 with promising results.

Apart from ICMR-Panacea Biotec, the Hyderabad-based Biological E Limited is also in the race to combat dengue fever.

Recently, Japanese pharma giant Takeda and Biological E limited announced collaboration to accelerate access to QDENGA (Dengue Tetravalent Vaccine) also known as TAK 003 developed by the Japanese pharma company.

Another pharma giant from State Capital, Indian Immunologicals Limited (IIL) is also in the process of developing a dengue vaccine and making it available commercially by early or mid-2026.

At present, the IIL, which is a subsidiary of National Dairy Development Board (NDDB), has successfully finished the first phase of clinical trials to vaccine's safety.

The phase 2 and phase 3 clinical trials of dengue vaccine by IIL are expected to be taken-up at the earliest and the vaccine likely to be launched in 2026.

The vaccine giant from Pune, Serum Institute has already received permission to conduct the phase I and 2 trials of its dengue vaccine labeled as Dengusiil.

In June of this year, the Serum Institute received a green signal from the Indian regulatory authorities to conduct the phase 2 trials of its dengue vaccine, after the promising results of the phase 1 trials.

The tetravalent live attenuated dengue vaccine is being manufactured in India by Serum Institute, which received the vaccine strains from National Institutes of Health (NIH), United States.

Fuente: Telangana Today. Disponible en https://acortar.link/PkMMIH

Expertos internacionales se reúnen en Cuba para estudiar el dengue y el oropouche

19 ago. Los especialistas se actualizarán y debatirán sobre la situación epidemiológica. Además, conocerán sobre los avances en el conocimiento, prevención y control de dengue y otras arbovirosis con especial referencia a chikungunya, zika, fiebre amarilla, mayaro y oropouche.

Dengue y oropouche, entre otros arbovirus, se encuentran en el foco de expertos internacionales que participan en La Habana en un curso organizado por el Instituto Pedro Kourí.

De acuerdo con Prensa Latina (PL), entre los objetivos de los especialistas está "la actualización y debate de la situación epidemiológica", así como "los avances en el conocimiento, prevención y control de dengue y otras arbovirosis con especial referencia a chikungunya, zika, fiebre amarilla, mayaro y oropouche".

Asimismo, suscribe la convocatoria citada por PL, los delegados conocerán acerca del manejo clínico de los pacientes, así como el control del vector, además de los avances en las investigaciones en patogenia.

También se pondrán al tanto sobre vacunas, genética del individuo, los virus y el vector, nuevas herramientas de control, además de la influencia del cambio climático en la emergencia de enfermedades transmitidas por mosquitos del género Aedes, agrega el medio.

A inicios de este mes, también científicos rusos iniciaron una visita a Cuba para estudiar varias enfermedades, entre ellas la Fiebre de Oropouche. Los especialistas pertenecen al Servicio Federal de Supervisión de la Protección y el Bienestar del Consumidor de Rusia (Rospotrebnadzor), entidad que informó que la visita tiene como objetivo "actualizarse sobre infecciones tropicales".

Rospotrebnadzor precisó que sus expertos realizarían, junto con sus colegas cubanos, una serie de estudios de actualidad sobre males que se registran en la región del Caribe.

Por primera vez, Cuba enfrenta en este verano la circulación de dos arbovirosis con una evolución inicial muy parecida en los pacientes que acuden a los servicios de salud, precisó un reporte reciente de televisión nacional.

"Hay presencia de casos de Oropouche en todas las provincias del país. Por lo tanto, aunque en un municipio determinado no haya circulación, si está en la provincia y usted viaja, puede ser objeto de la picada del mosquito", afirmó a finales de julio pasado la viceministra de Salud, Carilda Peña García, al actualizar la situación sanitaria a la isla.

Asimismo, en entrevista concedida al Canal Caribe, la funcionaria calificó al dengue como una enfermedad endémica. Explicó que "durante todos los meses del año aparecen casos sospechosos de la enfermedad; algunos se confirman, otros no".

Científicos cubanos esperan en un año tener una vacuna contra el dengue en la fase de estudios clínicos, anunció Gerardo Guillén Nieto, director de Investigaciones Biomédicas del Centro de Ingeniería Genética y Biotecnología (CIGB) de La Habana.

La fase I se refiere a la primera introducción de una vacuna en etapa experimental en una población humana para determinar inicialmente su seguridad y sus efectos biológicos, incluida la inmunogenicidad.

Esta fase puede incluir estudios de dosis y vías de administración y generalmente involucra a menos de 100 voluntarios.

En declaraciones a la agencia Prensa Latina, Guillén Nieto afirmó que el proyecto de vacuna para enfrentar el dengue es una prioridad dentro de la cartera de desarrollos del CIGB.

La presencia del dengue en Cuba se confirmó por primera vez en 1943, aunque es posible que haya sido la causa de una epidemia en 1902.

De acuerdo con estadísticas de la Organización Panamericana de la Salud, desde 2014 hasta la fecha Cuba ha reportado en dos años números que superan los 3 mil: 2019, con 3 mil 259 contagios y la circulación de dos cepas de la enfermedad; y 2022, con 3 mil 36 enfermos y la confirmación, por vez primera, de los cuatro serotipos de dengue en el territorio nacional.

Fuente: On Cuba News. Disponible en https://acortar.link/4SraoF

Con las vacunas antineumocócicas conjugadas se redujo la enfermedad invasiva en Latinoamérica, pero emergen serotipos no vacunales

20 ago. La introducción y el despliegue de las vacunas antineumocócicas conjugadas han logrado reducir de manera significativa las enfermedades invasivas por *Streptococcus pneumoniae* en Latinoamérica y el Caribe, evitando hospitalizaciones y salvando vidas de niños y adultos, confirma una revisión sistemática con metanálisis en PLOS ONE.

El grupo de investigación también constató que la vacunación favoreció el desplazamiento de serotipos cubiertos por los biológicos por otros no vacunales que también causan enfermedad, lo cual obliga a reforzar la vigilancia epidemiológica para monitorear de cerca este fenómeno y eventualmente sustentar la introducción de fórmulas que ofrezcan mayor cobertura.

"El cambio de serotipos también ocurre en otras infecciones, pero el efecto neto de la introducción de las vacunas ha sido muy benéfico en términos de la reducción de la carga de enfermedad", manifestó a Medscape en español el autor principal, Dr. Ariel Bardach, especialista en medicina interna y máster en epidemiología, investigador del Instituto de Efectividad Clínica y Sanitaria (IECS), en Buenos Aires, Argentina, y director del Centro de Investigaciones en Epidemiología y Salud Pública (CIESP), que depende del IECS y del Consejo Nacional de Investigaciones Científicas y Técnicas de Argentina (CONICET).

"El mensaje clave radica en que la vacuna es útil para prevenir enfermedad grave y secundariamente reducir la resistencia microbiana y el estrés del sistema de salud. ¿Cubren bien los serotipos circulantes? Sí. ¿Son infalibles? No. Y generan una selección natural de serotipos [no cubiertos por las vacunas]. Es como una competencia donde corremos a los microorganismos de atrás", indicó a Medscape en español la Dra. Miriam Rozenek, infectóloga y geriatra, exsecretaria del comité de vacunas de la Sociedad Argentina de Infectología (SADI) y directora del consejo de infectogeriatría de la Sociedad Argentina de Geriatría y Gerontología (SAGG), que no participó de la investigación.

Impacto de las vacunas sobre la carga de enfermedad

Las vacunas conjugadas son vacunas de polisacáridos capsulares purificados con diferentes serotipos de *S. pneumoniae*. La primera, heptavalente o PCV7, fue licenciada por la Administración de Alimentos y Fármacos (FDA) de Estados Unidos a fines del año 2000, aunque para 2008 México y Uruguay eran los

únicos países latinoamericanos que la habían incorporado en sus calendarios de vacunación para todos los niños. Con la llegada de nuevas fórmulas que cubren más serotipos, la decavalente o PCV10 (2009) y la 13 valente o PCV13 (2010), se extendió la adopción de la misma medida: en 2012 ya había 26 países y territorios en Latinoamérica y el Caribe que la aplicaban con distintos esquemas y para 2019 la cifra ya había subido a 35, aunque no todos incluían a los mayores de 65 años.

Fuente: Medscape. Disponible en https://acortar.link/J8ueoX

Cuba vacunará a su población contra el neumococo, la influenza y el papiloma humano

20 ago. Cuba aplicará a partir del próximo 9 de septiembre la vacuna antineumocócica Pneumosil-10, dirigida a la protección de los niños menores de un año, nacidos en 2024, contra diez serotipos de neumococo, informó este lunes José Angel Portal Miranda, ministro de Salud Pública, durante la apertura del XVIII Curso Internacional de Dengue y otros arbovirus emergentes.

Añadió que, como parte del esquema nacional de inmunización, cuando se disponga de la vacuna antineumocócica Quimi-Vio –desarrollada por el Instituto Finlay de Vacunas y actualmente en producción en el Centro Nacional de Biopreparados–, se aplicará a los niños de dos años de edad, nacidos en 2022.

Sobre las campañas de inmunización en el país, el doctor Francisco Durán García, director nacional de Epidemiología del Minsap, explicó a Granma que en el mes de agosto comenzó la aplicación de la vacuna antigripal, la cual previene el virus de influenza causante de cuadros respiratorios.

Detalló que se está aplicando a la población infantil de dos años, y para los adultos debe comenzar en el mes de septiembre o inicios de octubre, con énfasis en los grupos de riesgo, es decir, mayores de 60 años de edad, personas con enfermedad pulmonar obstructiva crónica, asmáticos y diabéticos, entre otros.

Durán García precisó que, a inicios de 2025, deben comenzar a aplicar la vacuna contra el virus del papiloma humano, una infección de transmisión sexual que provoca, como complicaciones fundamentales, el cáncer cérvicouterino en las mujeres y el cáncer anorrectal.

Amplió que esta vacuna se aplicará por primera vez en nuestro país a las niñas de nueve años de edad, y luego, cuando se adquieran más dosis, se extenderá a la población femenina hasta los 14 años. Su aplicación repercutirá en una disminución de estas formas de cáncer.

En el caso de las vacunas contra la COVID–19, precisó que se continúa aplicando un refuerzo para los grupos de riesgo, que debe concluir en el presente año.

Fuente: Mesa Redonda. Cubadebate. Disponible en https://acortar.link/Uo16ZT

Serum Institute says working to develop Monkeypox vaccine

Aug 20. The World Health Organisation on August 14 declared the Mpox outbreak a public health emergency of international concern. The move came after a sudden increase in cases was recorded in parts of Africa. In India, around 30 Mpox cases have been detected since 2022. The most recent case in the country was reported in March 2024.

Serum Institute of India on Tuesday said it is currently working to develop a vaccine for Monkeypox, with positive outcomes expected in a year's time. The World Health Organisation on August 14 declared the Mpox outbreak a public health emergency of international concern.

The move came after a sudden increase in cases was recorded in parts of Africa.

In India, around 30 Mpox cases have been detected since 2022. The most recent case in the country was reported in March 2024.

"In view of the global health emergency declared due to Mpox outbreak, Serum Institute of India is currently working on developing a vaccine for this disease to cater to millions of lives that might be at risk," Serum Institute of India CEO Adar Poonawalla said in a statement.

Hopefully, with the ongoing progress, the Pune-based vaccine major will have more updates and positive news to share within a year's time, he added.

The Union Health ministry has issued advisories highlighting that scrutiny at airports and seaports, especially at international entry points will increase.

The government has declared three hospitals -- Ram Manohar Lohia Hospital, Safdarjung Hospital, and Lady Hardinge Medical College -- as nodal centres for the isolation, management and treatment of patients.

Fuente: The Economic Times. Disponible en https://acortar.link/g2C6Ca

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2024/08/13"[Date - Publication] : "2024/08/20"[Date - Publication])) 694 records.

What's going on with measles?

Moss WJ, Griffin DE.J Virol. 2024 Aug 20;98(8):e0075824. doi: 10.1128/jvi.00758-24. Epub 2024 Jul 23.PMID: 39041786

The Bioethicist as Healer.

DuBois JM.Hastings Cent Rep. 2024 Aug 13. doi: 10.1002/hast.4901. Online ahead of print.PMID: 39136250

How do adjuvants enhance immune responses?

Rapaka RR.Elife. 2024 Aug 13;13:e101259. doi: 10.7554/eLife.101259.PMID: 39136115

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.

Hu X, Karthigeyan KP, Herbek S, Valencia SM, Jenks JA, Webster H, Miller IG, Connors M, Pollara J, Andy C, Gerber LM, Walter EB, Edwards KM, Bernstein DI, Hou J, Koch M, Panther L, Carfi A, Wu K, Permar SR.J Infect Dis. 2024 Aug 16;230(2):455-466. doi: 10.1093/infdis/jiad593.PMID: 38324766

Biomaterials-assisted cancer vaccine delivery: preclinical landscape, challenges, and opportunities.

Chen M, Zhou Y, Fu Y, Wang Q, Wu C, Pan X, Quan G.Expert Opin Drug Deliv. 2024 Aug 17:1-12. doi: 10.1080/17425247.2024.2388832. Online ahead of print.PMID: 39096307

Parental vaccine hesitancy and influenza vaccine type preferences during and after the COVID-19 Pandemic.

Yuan J, Li L, Dong M, So HC, Cowing BJ, Ip DKM, Liao Q.Commun Med (Lond). 2024 Aug 16;4(1):165. doi: 10.1038/s43856-024-00585-w.PMID: 39152249

Exposure proximal immune correlates analysis.

Huang Y, Follmann D.Biostatistics. 2024 Aug 14:kxae031. doi: 10.1093/biostatistics/kxae031. Online ahead of print.PMID: 39142660

Effectiveness of the 2023-2024 Formulation of the COVID-19 Messenger RNA Vaccine.

Shrestha NK, Burke PC, Nowacki AS, Gordon SM.Clin Infect Dis. 2024 Aug 16;79(2):405-411. doi: 10.1093/cid/ciae132.PMID: 38465901

The Development of Epitope-Based Recombinant Protein Vaccines against SARS-CoV-2.

Khalid K, Lim HX, Hwang JS, Poh CL.AAPS J. 2024 Aug 13;26(5):93. doi: 10.1208/s12248-024-00963-1.PMID: 39138686

COVID-19 and influenza vaccine uptake among pregnant women in national cohorts of England and Wales.

Gu X, Agrawal U, Midgley W, Bedston S, Anand SN, Goudie R, Byford R, Joy M, Jamie G, Hoang U, Ordóñez-Mena JM, Robertson C, Hobbs FDR, Akbari A, Sheikh A, de Lusignan S.NPJ Vaccines. 2024 Aug 14;9(1):147. doi: 10.1038/s41541-024-00934-9.PMID: 39143081

Hesitant but vaccinated: Lessons learned from hesitant adopters.

Willis DE, Moore R, Purvis RS, McElfish PA.Vaccine. 2024 Aug 13;42(20):126135. doi: 10.1016/j.vaccine.2024.07.036. Epub 2024 Jul 27.PMID: 39068065

Variant-Specific IgA Protects Against Omicron Infection.

Goh YS, Fong SW, Hor PX, Loh CY, Wang B, Salleh SNM, Ngoh EZX, Lee RTC, Poh XY, Rao S, Chia PY, Ong SWX, Lee TH, Lim C, Teo J, Pada S, Sun LJ, Ong DLS, Somani J, Lee ES, Maurer-Stroh S, Wang CI, Leo YS, Lye DC, Young BE, Ng LFP, Renia L; NCID Study Group; COVID-19 Cohort Study Group.J Infect Dis. 2024 Aug 16;230(2):e287-e291. doi: 10.1093/infdis/jiad525.PMID: 37996071

Lipid- and Polymer-Based Nanocarrier Platforms for Cancer Vaccine Delivery.

Sunoqrot S, Abdel Gaber SA, Abujaber R, Al-Majawleh M, Talhouni S.ACS Appl Bio Mater. 2024 Aug 19;7(8):4998-5019. doi: 10.1021/acsabm.3c00843. Epub 2024 Jan 18.PMID: 38236081

Top advances of the year: Melanoma.

Khattak MA, Luke JJ.Cancer. 2024 Aug 15;130(16):2733-2738. doi: 10.1002/cncr.35354. Epub 2024 Apr 29.PMID: 38682653

T-Cell Responses to Treponema pallidum Proteins in Blood and Skin to Advance Syphilis Vaccine Design: Learning From Nature.

Salazar JC, Radolf JD.J Infect Dis. 2024 Aug 16;230(2):275-277. doi: 10.1093/infdis/jiae246.PMID: 39147388

Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.

Henríquez R, Muñoz-Barroso I.Heliyon. 2024 Jul 20;10(15):e34927. doi: 10.1016/j.heliyon.2024.e34927. eCollection 2024 Aug 15.PMID: 39144987

Biogenesis and Functionality of Sortase-Assembled Pili in Gram-Positive Bacteria.

Chang C, Ramirez NA, Bhat AH, Nguyen MT, Kumari P, Ton-That H, Das A, Ton-That H.Annu Rev Microbiol. 2024 Aug 14. doi: 10.1146/annurev-micro-112123-100908. Online ahead of print.PMID: 39141696

Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1 + 1 infant schedule in England: a modelling study.

Choi YH, Bertran M, Litt DJ, Ladhani SN, Miller E.Lancet Public Health. 2024 Aug 14:S2468-2667(24)00161-0. doi: 10.1016/S2468-2667(24)00161-0. Online ahead of print.PMID: 39153492

Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.

Chalkias S, McGhee N, Whatley JL, Essink B, Brosz A, Tomassini JE, Girard B, Edwards DK, Wu K, Nasir A, Lee D, Avena LE, Feng J, Deng W, Montefiori DC, Baden LR, Miller JM, Das R.J Infect Dis. 2024 Aug 16;230(2):e279-e286. doi: 10.1093/infdis/jiae067.PMID: 38349280

Global perspectives on smallpox vaccine against monkeypox: a comprehensive meta-analysis and systematic review of effectiveness, protection, safety and cross-immunogenicity.

Liu H, Wang W, Zhang Y, Wang F, Duan J, Huang T, Huang X, Zhang T.Emerg Microbes Infect. 2024 Dec;13(1):2387442. doi: 10.1080/22221751.2024.2387442. Epub 2024 Aug 16.PMID: 39082272

Vaccination to Prevent Lyme Disease: A Movement Towards Anti-Tick Approaches.

Johnson EE, Hart TM, Fikrig E.J Infect Dis. 2024 Aug 14;230(Supplement_1):S82-S86. doi: 10.1093/infdis/jiae202.PMID: 39140718

Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-Dose Influenza Vaccine in Adults 65 Years and Older: A Noninferiority Trial.

Widagdo W, Bastian AR, Jastorff AM, Scheys I, De Paepe E, Comeaux CA, Ligtenberg N, Callendret B, Heijnen E.J Infect Dis. 2024 Aug 16;230(2):e374-e383. doi: 10.1093/infdis/jiad594.PMID: 38134393

Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report.

Balasingam S, Dheda K, Fortune S, Gordon SB, Hoft D, Kublin JG, Loynachan CN, McShane H, Morton B, Nambiar S, Sharma NR, Robertson B, Schrager LK, Weller CL.J Infect Dis. 2024 Aug 16;230(2):e457-e464. doi: 10.1093/infdis/jiae238.PMID: 38709726

Routines, disruptions, revised decisions: A biographical analysis of vaccination trajectories among Filipino caregivers.

Wachinger J, Reñosa MDC, Endoma V, Landicho-Guevarra J, McMahon SA.Vaccine. 2024 Aug 13;42(20):126095. doi: 10.1016/j.vaccine.2024.06.062. Epub 2024 Jul 6.PMID: 38972765

COVID-19 Vaccine Efficacy in Participants With Weakened Immune Systems From 4 Randomized Controlled Trials.

Sherman AC, Tuan J, Cantos VD, Adeyiga O, Mahoney S, Ortega-Villa AM, Tillman A, Whitaker J, Woodward Davis AS, Leav B, Hirsch I, Sadoff J, Dunkle LM, Gilbert PB, Janes HE, Kublin JG, Goepfert PA, Kotloff K, Rouphael N, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, Neuzil KM, Corey L, Grinsztejn B, Gray G, Nason M, Baden LR, Gay CL.Clin Infect Dis. 2024 Aug 16;79(2):364-374. doi: 10.1093/cid/ciae192.PMID: 38598658

Immunization with an mRNA DTP vaccine protects against pertussis in rats.

Bitzer GJ, Fitzgerald NA, DeJong MA, Cunningham C, Chapman JA, Boehm DT, Pyles GM, Huckaby AB, Miller SJ, Dublin SR, Warden MD, Barbier M, Damron FH.Infect Immun. 2024 Aug 13;92(8):e0052023. doi: 10.1128/iai.00520-23. Epub 2024 Jul 17.PMID: 39016553

Comparison of the efficacy of COVID-19 responses in South Korea and the United States.

Choi O, Kim S.Glob Health Action. 2024 Dec 31;17(1):2370611. doi: 10.1080/16549716.2024.2370611. Epub 2024 Aug 13.PMID: 39135484

High recallability of memory B cells requires ZFP318-dependent transcriptional regulation of mitochondrial function.

Wang Y, Shao W, Liu X, Liang Q, Lei J, Shi W, Mei M, Li Y, Tan X, Yu G, Yu L, Zhang L, Qi H.Immunity. 2024 Aug 13;57(8):1848-1863.e7. doi: 10.1016/j.immuni.2024.05.022. Epub 2024 Jun 17.PMID: 38889716

Rotavirus infections and their genotype distribution pre- and post-vaccine introduction in Ethiopia: a systemic review and meta-analysis.

Tosisa W, Regassa BT, Eshetu D, Irenso AA, Mulu A, Hundie GB.BMC Infect Dis. 2024 Aug 16;24(1):836. doi: 10.1186/s12879-024-09754-7.PMID: 39152402

Specialized Vaccine Care for Adverse Events Following Immunization and Impact on Vaccine Hesitancy in the Military Health System.

Loran DA, Angelo S, Ryan M.Mil Med. 2024 Aug 19;189(Supplement_3):546-550. doi: 10.1093/milmed/usae182.PMID: 39160803

Evidence Gaps in Economic Evaluations of HIV Interventions Targeting Young People: A Systematic Review.

Zimmerman A, Fawole A, Shahid M, Dow D, Ogbuoji O.J Adolesc Health. 2024 Aug 13:S1054-139X(24)00296-9. doi: 10.1016/j.jadohealth.2024.06.013. Online ahead of print.PMID: 39140926

The Novavax Heterologous Coronavirus Disease 2019 Booster Demonstrates Lower Reactogenicity Than Messenger RNA: A Targeted Review.

Marchese AM, Rousculp M, Macbeth J, Beyhaghi H, Seet BT, Toback S.J Infect Dis. 2024 Aug 16;230(2):e496-e502. doi: 10.1093/infdis/jiad519.PMID: 37992183

Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (MENIQUE).

Hernández-Bernal F, Noa-Romero E, Quintana-Guerra J, Chávez-Chong CO, Martín-Bauta Y, Alvaré-Alvaré L, Salvato-Dueñas A, Felipe-Mallea D, Porta-Díaz M, Cruz-Sui O, Urrutia-Pérez K, Urrutia-Pérez K, Rodríguez-Reinoso JL, Alonso-Valdés M, Cinza-Estévez Z, Rodríguez-Triana A, Cruz-Gómez Y, Limonta-Fernández M, Rodríguez-Acosta M, Ayala-Ávila M, Muzio-González VL; ABDALA Group of Investigators.Vaccine. 2024 Aug 15;42(22):126223. doi: 10.1016/j.vaccine.2024.126223. Online ahead of print.PMID: 39151232

Opportunities and challenges to the development and deployment of vaccines for pregnant women in Germany.

Pley C, Kampmann B.Vaccine. 2024 Aug 13;42(20):126094. doi: 10.1016/j.vaccine.2024.06.061. Epub 2024 Jun 29.PMID: 38944576

Changes in vaccination uptake against pneumococcal disease, influenza, and coronavirus disease 2019 (COVID-19) before and after a Head and Neck cancer diagnosis.

Eiberg MF, Rezahosseini O, Bukan KB, Charlotte Arp B, Le VB, Ahmad F, Howitz M, Lendorf M, Friborg J, Lindegaard B, Harboe ZB.Vaccine. 2024 Aug 13;42(20):125972. doi: 10.1016/j.vaccine.2024.05.021. Epub 2024 May 24.PMID: 38789370

Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine.

Westercamp N, Osei-Tutu L, Schuerman L, Kariuki SK, Bollaerts A, Lee CK, Samuels AM, Ockenhouse C, Bii DK, Adjei S, Oneko M, Lievens M, Attobrah Sarfo MA, Atieno C, Bakari A, Sang T, Kotoh-Mortty MF, Otieno K, Roman F, Buabeng PBY, Ntiamoah Y, Ansong D, Agbenyega T, Ofori-Anyinam O.J Infect Dis. 2024 Aug 16;230(2):e486-e495. doi: 10.1093/infdis/jiae075.PMID: 38438123

Do self-rated health and previous vaccine uptake influence the willingness to accept MPOX vaccine during a public health emergency of concern? A cross-sectional study.

Braimah JA, Achore M, Dery F, Ayanore MA, Bisung E, Kuuire V.PLOS Glob Public Health. 2024 Aug 15;4(8):e0003564. doi: 10.1371/journal.pgph.0003564. eCollection 2024.PMID: 39146333

Receptiveness to monkeypox vaccines and public health communication strategies among gay, bisexual and other men who have sex with men in Singapore: cross-sectional quantitative and qualitative insights.

Chan ZYS, Chong SY, Niaupari S, Harrison-Quintana J, Lim JT, Dickens B, Kularathne Y, Wong CS, Tan RKJ.Sex Transm Infect. 2024 Aug 19;100(6):362-367. doi: 10.1136/sextrans-2024-056230.PMID: 38821878

Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.

Diawara H, Healy SA, Mwakingwe-Omari A, Issiaka D, Diallo A, Traore S, Soumbounou IH, Gaoussou S, Zaidi I, Mahamar A, Attaher O, Fried M, Wylie BJ, Mohan R, Doan V, Doritchamou JYA, Dolo A, Morrison RD, Wang J, Hu Z, Rausch KM, Zeguime A, Murshedkar T, Kc N, Sim BKL, Billingsley PF, Richie TL, Hoffman SL, Dicko A, Duffy PE; PfSPZ Vaccine Study Team.Lancet Infect Dis. 2024 Aug 14:S1473-3099(24)00360-8. doi: 10.1016/S1473-3099(24)00360-8. Online ahead of print.PMID: 39153490

Reported Barriers and Facilitators for Autistic Individuals, Persons with Other Intellectual and Developmental Disabilities, and Their Caregivers to Receive the COVID-19 Vaccine: A Pilot Study.

Resnikoff AW, Colantuono V, Wieckowski AT, Chernak E, Plumb J, Baynard M, Sheridan E, Robins DL.J Autism Dev Disord. 2024 Aug 16. doi: 10.1007/s10803-024-06506-z. Online ahead of print.PMID: 39150481

Immune imprinting: The persisting influence of the first antigenic encounter with rapidly evolving viruses.

Maltseva M, Keeshan A, Cooper C, Langlois MA.Hum Vaccin Immunother. 2024 Dec 31;20(1):2384192. doi: 10.1080/21645515.2024.2384192. Epub 2024 Aug 16.PMID: 39149872

Vaccine-Preventable Disease Outbreaks Among Healthcare Workers: A Scoping Review.

Hasan T, Lynch M, King C, Wehbe C, Plymoth M, Islam MS, Iannuzzi T, Dao A, Lai J, Martiniuk A, Desai S, Sheel M.Clin Infect Dis. 2024 Aug 16;79(2):555-561. doi: 10.1093/cid/ciae209.PMID: 38630638

COVID-19 vaccination and concerns regarding vaccine hesitancy after the termination of the zero-COVID policy in China: A nationwide cross-sectional study.

Yang M, Ma W, Jiang J, Lu Z, Wang X, Shen Y, Zou H, Meng X.Hum Vaccin Immunother. 2024 Dec 31;20(1):2388938. doi: 10.1080/21645515.2024.2388938. Epub 2024 Aug 14.PMID: 39140437

HPV vaccination intention among guardians of female secondary school students in Chongqing, China.

Bai N, Wang Q, Shao J, Chen L, Wang C, Xiao X, Yu L, Xu B.Hum Vaccin Immunother. 2024 Dec 31;20(1):2381293. doi: 10.1080/21645515.2024.2381293. Epub 2024 Aug 14.PMID: 39143812

Current Approaches in Postapproval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published Literature.

Wu JJ, Hauben M, Younus M.Clin Ther. 2024 Aug 13:S0149-2918(24)00142-5. doi: 10.1016/j.clinthera.2024.06.005. Online ahead of print.PMID: 39142925

Influences of HPV disease perceptions, vaccine accessibility, and information exposure on social media on HPV vaccination uptake among 11,678 mothers with daughters aged 9-17 years in China: a cross-sectional study.

Lin Z, Chen S, Su L, Liao Y, Chen H, Hu Z, Chen Z, Fang Y, Liang X, Chen J, Luo B, Wu C, Wang Z.BMC Med. 2024 Aug 13;22(1):328. doi: 10.1186/s12916-024-03538-1.PMID: 39135035

Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.

Chihana R, Jin Kee J, Moodie Z, Huang Y, Janes H, Dadabhai S, Roxby AC, Allen M, Kassim S, Naicker V, Innes C, Naicker N, Dubula T, Grunenberg N, Malahleha M, Kublin JG, Bekker LG, Gray G, Kumwenda J, Laher F.Vaccine. 2024 Aug 13;42(20):125991. doi: 10.1016/j.vaccine.2024.05.039. Epub 2024 May 21.PMID: 38772835

The development of a human Brucella mucosal vaccine: What should be considered?

Tian T, Zhu Y, Shi J, Shang K, Yin Z, Shi H, He Y, Ding J, Zhang F.Life Sci. 2024 Aug 14:122986. doi: 10.1016/j.lfs.2024.122986. Online ahead of print.PMID: 39151885

Comparative immunogenicity of monovalent and bivalent adenovirus vaccines carrying spikes of early and late SARS-CoV-2 variants.

Li H, Yang C, Yin L, Liu W, Zhang Z, Liu B, Sun X, Liu W, Lin Z, Liu Z, He P, Feng Y, Wang C, Wang W, Guan S, Wang Q, Chen L, Li P.Emerg Microbes Infect. 2024 Dec;13(1):2387447. doi: 10.1080/22221751.2024.2387447. Epub 2024 Aug 19.PMID: 39082740

Expression, Purification, and Evaluation of Antibody Responses and Antibody-Immunogen Complex Simulation of a Designed Multi-Epitope Vaccine against SARS-COV-2.

Jamal GA, Jahangirian E, Tarrahimofrad H.Protein Pept Lett. 2024 Aug 19. doi: 10.2174/0109298665320319240809095727. Online ahead of print.PMID: 39162285

Understanding Mucosal Physiology and Rationale of Formulation Design for Improved Mucosal Immunity.

Biswas M, Nurunnabi M, Khatun Z.ACS Appl Bio Mater. 2024 Aug 19;7(8):5037-5056. doi: 10.1021/acsabm.4c00395. Epub 2024 May 24.PMID: 38787767

Development of T cell antigen-based human coronavirus vaccines against nAb-escaping SARS-CoV-2 variants.

Zhou H, Leng P, Wang Y, Yang K, Li C, Ojcius DM, Wang P, Jiang S.Sci Bull (Beijing). 2024 Aug 15;69(15):2456-2470. doi: 10.1016/j.scib.2024.02.041. Epub 2024 Jun 12.PMID: 38942698

An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.

de La Vega MA, Xiii A, Massey S, Spengler JR, Kobinger GP, Woolsey C.Expert Opin Drug Discov. 2024 Aug 18:1-27. doi: 10.1080/17460441.2024.2386100. Online ahead of print.PMID: 39090822

CodonBERT large language model for mRNA vaccines.

Li S, Moayedpour S, Li R, Bailey M, Riahi S, Kogler-Anele L, Miladi M, Miner J, Pertuy F, Zheng D, Wang J, Balsubramani A, Tran K, Zacharia M, Wu M, Gu X, Clinton R, Asquith C, Skaleski J, Boeglin L, Chivukula S, Dias A, Strugnell T, Montoya FU, Agarwal V, Bar-Joseph Z, Jager S.Genome Res. 2024 Aug 20;34(7):1027-1035. doi: 10.1101/gr.278870.123.PMID: 38951026

SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study.

Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Howard DS, Ibrahim U, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, Horowitz MM, Riches ML, Perales MA.Clin Infect Dis. 2024 Aug 16;79(2):542-554. doi: 10.1093/cid/ciae291.PMID: 38801746

Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters.

Zhang XS, Windau A, Meyers J, Yang X, Dong F.Microbiol Spectr. 2024 Aug 20:e0060524. doi: 10.1128/spectrum.00605-24. Online ahead of print.PMID: 39162540

Uptake and outcomes of VaxCheck, an adult life-course vaccination service: A study among community pharmacists.

Houle SKD, Waite NM, Vernon-Wilson E, Dolovich L, Yang M.Vaccine. 2024 Aug 13;42(20):126096. doi: 10.1016/j.vaccine.2024.06.063. Epub 2024 Jul 1.PMID: 38955590

Engineering receptor-binding domain and heptad repeat domains towards the development of multi-epitopes oral vaccines against SARS-CoV-2 variants.

Arshad NF, Nordin FJ, Foong LC, In LLA, Teo MYM.PLoS One. 2024 Aug 15;19(8):e0306111. doi: 10.1371/journal.pone.0306111. eCollection 2024.PMID: 39146295

Phagolysosomal resistance hypothesized to be a danger signal.

Forden CA.Scand J Immunol. 2024 Aug 13:e13400. doi: 10.1111/sji.13400. Online ahead of print.PMID: 39138895

Geographic information system and information visualization capacity building: Successful polio eradication and current and future challenges in the COVID-19 era for the World Health Organization's African region.

Kipterer JK, Touray K, Godwin AU, Cisse A, Aimee BNM, Busisiwe N, Derrick CYD, Henry GH, Modjirom N, Seaman V, Ahmed J.PLoS One. 2024 Aug 15;19(8):e0307001. doi: 10.1371/journal.pone.0307001. eCollection 2024.PMID: 39146252

Maternal Immunization Decision-Making Among Pregnant and Lactating People in Kenya: A Qualitative Exploration of Peer Influences on Vaccine Decision-Making for a Future RSV Vaccine.

Singh P, Fesshaye B, Lee C, Njogu RN, Karron RA, Limaye RJ.Matern Child Health J. 2024 Aug 14. doi: 10.1007/s10995-024-03982-8. Online ahead of print.PMID: 39141202

Long-term Sudan Virus Ebola Survivors Maintain Multiple Antiviral Defense Mechanisms.

Sobarzo A, Moné Y, Lang S, Gelkop S, Brangel P, Kuehne AI, McKendry RA, Mell JC, Ahmed A, Davis C, Dye JM, Lutwama JJ, Lobel L, Veas F, Ehrlich GD.J Infect Dis. 2024 Aug 16;230(2):426-437. doi: 10.1093/infdis/jiad555.PMID: 38066574

Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.

Hermida N, Ferguson M, Leroux-Roels I, Pagnussat S, Yaplee D, Hua N, van den Steen P, Anspach B, Dieussaert I, Kim JH.J Infect Dis. 2024 Aug 16;230(2):e353-e362. doi: 10.1093/infdis/jiad560.PMID: 38133639

Sex-based difference in immune responses and efficacy of the pneumococcal conjugate vaccine.

Tchalla EYI, Betadpur A, Khalil AY, Bhalla M, Bou Ghanem EN.J Leukoc Biol. 2024 Aug 14:qiae177. doi: 10.1093/jleuko/qiae177. Online ahead of print.PMID: 39141715

Immunogenicity of a 30-valent M protein mRNA group A Streptococcus vaccine.

Finn MB, Penfound TA, Salehi S, Ogega CO, Dold C, Plante O, Dale JB.Vaccine. 2024 Aug 13;42(22):126205. doi: 10.1016/j.vaccine.2024.126205. Online ahead of print.PMID: 39141987

Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years.

Tsampalieros A, Zemek R, Barrowman N, Langlois MA, Arnold C, McGahern C, Plint AC, Pham-Huy A, Bhatt M.Vaccine. 2024 Aug 13;42(20):125981. doi: 10.1016/j.vaccine.2024.05.029. Epub 2024 May 23.PMID: 38789373

Selenium nanoparticles enhance mucosal immunity against Mycobacterium bovis infection.

Ge X, Liang Z, Li K, Dong Y, Wang Y, Liu Y, Liu Z, Wang H, Nan Y, Chen S, Li L, Guo Y, Zhou X.Int Immunopharmacol. 2024 Aug 20;137:112384. doi: 10.1016/j.intimp.2024.112384. Epub 2024 Jun 14.PMID: 38878484

Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.

Meo SA, Shaikh N, Abukhalaf FA, Meo AS.Sci Rep. 2024 Aug 13;14(1):18767. doi: 10.1038/s41598-024-66999-7.PMID: 39138276

Nirsevimab: Alleviating the burden of RSV morbidity in young children.

Loe MWC, Soenong H, Lee E, Li-Kim-Moy J, Williams PC, Yeo KT.J Paediatr Child Health. 2024 Aug 16. doi: 10.1111/jpc.16643. Online ahead of print.PMID: 39150043

Structure and inhibition of SARS-CoV-2 spike refolding in membranes.

Grunst MW, Qin Z, Dodero-Rojas E, Ding S, Prévost J, Chen Y, Hu Y, Pazgier M, Wu S, Xie X, Finzi A, Onuchic JN, Whitford PC, Mothes W, Li W.Science. 2024 Aug 16;385(6710):757-765. doi: 10.1126/science.adn5658. Epub 2024 Aug 15.PMID: 39146425

Changes in vaccine hesitancy among parents of children aged 6 months - 17 Years, National Immunization Surveys, 2019-2022.

Vashist K, Yankey D, Elam-Evans LD, Mu Y, Valier MR, Pingali C, Hill HA, Santibanez TA, Singleton JA.Vaccine. 2024 Aug 13;42(20):125989. doi: 10.1016/j.vaccine.2024.05.037. Epub 2024 May 27.PMID: 38806351

T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination.

Verstegen NJM, Hagen RR, Kreher C, Kuijper LH, Dijssel JVD, Ashhurst T, Kummer LYL, Palomares Cabeza V, Steenhuis M, Duurland MC, Jongh R, Schoot CEV, Konijn VAL, Mul E, Kedzierska K, van Dam KPJ, Stalman EW, Boekel L, Wolbink G, Tas SW, Killestein J, Rispens T, Wieske L, Kuijpers TW, Eftimov F, van Kempen ZLE, van Ham SM, Ten Brinke A, van de Sandt CE; T2B! immunity against SARS-CoV-2 study group.J Neurol Neurosurg Psychiatry. 2024 Aug 16;95(9):855-864. doi: 10.1136/jnnp-2023-332224.PMID: 38548324

Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.

Snider CJ, Zaman K, Estivariz CF, Aziz AB, Yunus M, Haque W, Hendley WS, Weldon WC, Oberste MS, Pallansch MA, Wassilak SGF, Anand A.Vaccine. 2024 Aug 14;42(22):126216. doi: 10.1016/j.vaccine.2024.126216. Online ahead of print.PMID: 39146859

Assessing ventilation through ambient carbon dioxide concentrations across multiple healthcare levels in Ghana.

Crews C, Angwaawie P, Abdul-Mumin A, Yabasin IB, Attivor E, Dibato J, Coffee MP.PLOS Glob Public Health. 2024 Aug 14;4(8):e0003287. doi: 10.1371/journal.pgph.0003287. eCollection 2024.PMID: 39141637

Profiling vaccine hesitancy in nursing to tailor public healthcare policies: A cross-sectional international study.

McCready J, Erfani G, Comparcini D, Cicolini G, Mikkonen K, Keisala J, Tomietto M; Sigma IMPACT Research team.J Nurs Scholarsh. 2024 Aug 14. doi: 10.1111/jnu.13016. Online ahead of print.PMID: 39143721

Effect of SARS-CoV-2 vaccination on the outcomes of assisted reproductive technology: A review.

Kong X, Shen C, Liu T, Yang A, Liu X, Hou F, Wang W, Yang S, Li Z, Wang J.Medicine (Baltimore). 2024 Aug 16;103(33):e39310. doi: 10.1097/MD.0000000000039310.PMID: 39151499

Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.

Yeganeh N, Yin S, Moir O, Danza P, Kim M, Finn L, Fisher R, Kulkarni S, Perez M, Poortinga K, Garland W, Foo C, Haddix M, Archer R, Frey N, Balter S, Singhal R, Kim A.Vaccine. 2024 Aug 13;42(20):125987. doi: 10.1016/j.vaccine.2024.05.035. Epub 2024 May 24.PMID: 38789368

Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.

Ihenetu G, Aylin P, Novov V, Skirrow H, Saxena S, Majeed A, Woodcock T.Vaccine. 2024 Aug 13:126214. doi: 10.1016/j.vaccine.2024.126214. Online ahead of print.PMID: 39142904

Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.

[No authors listed]J Infect Dis. 2024 Aug 16;230(2):e504. doi: 10.1093/infdis/jiae336.PMID: 38959419

Immunogenicity of a peptide-based vaccine for measles: a pilot evaluation in a mouse model.

Quach HQ, Ratishvili T, Haralambieva IH, Ovsyannikova IG, Poland GA, Kennedy RB.Sci Rep. 2024 Aug 13;14(1):18776. doi: 10.1038/s41598-024-69825-2.PMID: 39138335

Caveats Regarding the Test-Negative Design to Study Mpox (monkeypox) Risk Factors and Vaccine Effectiveness.

Núñez I.Am J Epidemiol. 2024 Aug 14:kwae284. doi: 10.1093/aje/kwae284. Online ahead of print.PMID: 39142690

Infant and adult human intestinal enteroids are morphologically and functionally distinct.

Adeniyi-Ipadeola GO, Hankins JD, Kambal A, Zeng X-L, Patil K, Poplaski V, Bomidi C, Nguyen-Phuc H, Grimm SL, Coarfa C, Stossi F, Crawford SE, Blutt SE, Speer AL, Estes MK, Ramani S.mBio. 2024 Aug 14;15(8):e0131624. doi: 10.1128/mbio.01316-24. Epub 2024 Jul 2.PMID: 38953637

A spike-based mRNA vaccine that induces durable and broad protection against porcine deltacoronavirus in piglets.

Li J, Xiao L, Chen Z, Fan L, Wang W, Guo R, He Z, Hu H, Jiang J, Zhao L, Zhong T, Fan B, Zhu X, Li B.J Virol. 2024 Aug 19:e0053524. doi: 10.1128/jvi.00535-24. Online ahead of print.PMID: 39158273

The Elimination Status of Visceral Leishmaniasis in Southeast Asia Region.

Rahim S, Karim MM.Acta Parasitol. 2024 Aug 20. doi: 10.1007/s11686-024-00880-5. Online ahead of print.PMID: 39162927

Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study.

Jayasinghe S, Williams PCM, Macartney KK, Crawford NW, Blyth CC.Clin Infect Dis. 2024 Aug 14:ciae377. doi: 10.1093/cid/ciae377. Online ahead of print.PMID: 39140767

A nucleoside-modified mRNA vaccine forming rabies virus-like particle elicits strong cellular and humoral immune responses against rabies virus infection in mice.

Liu J, Sun J, Ding X, Liu W, Wang Y, Wang Z, Peng H, Zhang Y, Su W, Jiang C.Emerg Microbes Infect. 2024 Dec;13(1):2389115. doi: 10.1080/22221751.2024.2389115. Epub 2024 Aug 14.PMID: 39129566

Efficacy of a stable broadly protective subunit vaccine platform against SARS-CoV-2 variants of concern.

Garg R, Liu Q, Van Kessel J, Asavajaru A, Uhlemann EM, Joessel M, Hamonic G, Khatooni Z, Kroeker A, Lew J, Scruten E, Pennington P, Deck W, Prysliak T, Nickol M, Apel F, Courant T, Kelvin AA, Van Kessel A, Collin N, Gerdts V, Köster W, Falzarano D, Racine T, Banerjee A.Vaccine. 2024 Aug 13;42(20):125980. doi: 10.1016/j.vaccine.2024.05.028. Epub 2024 May 19.PMID: 38769033

Modulating Elasticity of Liposome for Enhanced Cancer Immunotherapy.

Yuan P, Yan X, Zong X, Li X, Yang C, Chen X, Li Y, Wen Y, Zhu T, Xue W, Dai J.ACS Nano. 2024 Aug 14. doi: 10.1021/acsnano.4c09094. Online ahead of print.PMID: 39140567

Comparison of Adverse Events and Antibody Responses Among Different COVID-19 Vaccination Schedules.

Pinto ACMD, Silva MFS, Oliveira FCE, Garcia MML, Melo VB, Damasceno GA, Matsui TC, Fonseca MHG.Viral Immunol. 2024 Aug 16. doi: 10.1089/vim.2024.0019. Online ahead of print.PMID: 39149804

Exploring the pathogenicity of Mycoplasma pneumoniae: Focus on community-acquired respiratory distress syndrome toxins.

Xu N, Fan L, Li L, Guo Y.Microb Pathog. 2024 Aug 15:106865. doi: 10.1016/j.micpath.2024.106865. Online ahead of print.PMID: 39153578

The broader benefits of vaccines: methodologies for inclusion in economic evaluation.

Simoens S, Tubeuf S, Dauby N, Ethgen O, Marbaix S, Willaert M, Luyten J.Expert Rev Vaccines. 2024 Aug 13. doi: 10.1080/14760584.2024.2387599. Online ahead of print.PMID: 39136368

A review on RNA interference studies in Anophelines to reveal candidate genes for malaria transmission blocking vaccine.

Yadav M, Dahiya N, Janjoter S, Kataria D, Dixit R, Sehrawat N.Life Sci. 2024 Aug 15;351:122822. doi: 10.1016/j.lfs.2024.122822. Epub 2024 Jun 10.PMID: 38866221

A broad-spectrum vaccine candidate against H5 viruses bearing different sub-clade 2.3.4.4 HA genes.

Zhang Y, Cui P, Shi J, Zeng X, Jiang Y, Chen Y, Zhang J, Wang C, Wang Y, Tian G, Chen H, Kong H, Deng G.NPJ Vaccines. 2024 Aug 19;9(1):152. doi: 10.1038/s41541-024-00947-4.PMID: 39160189

rAAV expressing a COBRA-designed influenza hemagglutinin generates a protective and durable adaptive immune response with a single dose.

Wiggins KB, Winston SM, Reeves IL, Gaevert J, Spence Y, Brimble MA, Livingston B, Morton CL, Thomas PG, Sant AJ, Ross TM, Davidoff AM, Schultz-Cherry S.J Virol. 2024 Aug 20;98(8):e0078124. doi: 10.1128/jvi.00781-24. Epub 2024 Jul 30.PMID: 39078191

Prediction of differential Gag versus Env responses to a mosaic HIV-1 vaccine regimen by HLA class I alleles.

Nelson GW, van Duijn J, Yuki Y, Pau MG, Tomaka F, Lavreys L, DeRosa SC, McElrath MJ, Kirk GD, Michael NL, Haas DW, Deeks SG, Wolinsky S, Walker B, Barouch DH, Stieh D, Carrington M.J Virol. 2024 Aug 20;98(8):e0028124. doi: 10.1128/jvi.00281-24. Epub 2024 Jul 24.PMID: 39046263

In vitro identification of neutralizing epitopes of Rhipicephalus microplus serpin 17 (RmS-17).

de Albuquerque PMM, Kotál J, Juliano MA, Tirloni L, da Silva Vaz I Jr.Vaccine. 2024 Aug 13;42(20):126161. doi: 10.1016/j.vaccine.2024.126161. Epub 2024 Jul 26.PMID: 39060200

Bacterial Membrane Vesicles as a Novel Vaccine Platform against SARS-CoV-2.

Yılmaz Çolak Ç.Curr Microbiol. 2024 Aug 20;81(10):317. doi: 10.1007/s00284-024-03846-y.PMID: 39164527

Retraction notice to "Development of novel HPV therapeutic vaccine constructs based on engineered exosomes and tumor cell lysates" [Life Sci. 340 (2024) 122456].

Rezaei F, Bolhassani A, Sadat SM, Arashkia A, Fotouhi F, Milani A, Pordanjani PM.Life Sci. 2024 Aug 15;351:122831. doi: 10.1016/j.lfs.2024.122831. Epub 2024 Jun 12.PMID: 38866604

Engineered mitochondria exert potent antitumor immunity as a cancer vaccine platform.

Luo J, Mo F, Zhang Z, Hong W, Lan T, Cheng Y, Fang C, Bi Z, Qin F, Yang J, Zhang Z, Li X, Que H, Wang J, Chen S, Wu Y, Yang L, Li J, Wang W, Chen C, Wei X.Cell Mol Immunol. 2024 Aug 20. doi: 10.1038/s41423-024-01203-4. Online ahead of print.PMID: 39164536

The significance of stem cell-like memory T cells in viral and bacterial vaccines: A mini review.

Fazeli P, Kalani M, Mahdavi M, Hosseini M.Int Immunopharmacol. 2024 Aug 20;137:112441. doi: 10.1016/j.intimp.2024.112441. Epub 2024 Jun 9.PMID: 38852525

Varying the hydrophobic core composition of polymeric nanoparticles affects NLRP3 inflammasome activation.

Malhotra M, Chotaliya D, Debnath M, Patel R, Kulkarni A.Biomater Sci. 2024 Aug 14. doi: 10.1039/d4bm00580e. Online ahead of print.PMID: 39140798

Mammalian cell expressed recombinant trimeric spike protein is a potent vaccine antigen and confers near-complete protection against SARS-CoV-2 infection in Hamster.

Jitender, Vikram Kumar B, Singh S, Verma G, Kumar R, Mishra PM, Kumar S, Nagaraj SK, Nag J, Joy CM, Nikam B, Singh D, Pooja, Kalidas N, Singh S, Mumtaz, Bhardwaj AK, Mankotia DS, Ringe RP, Gupta N, Tripathi S, Mishra RPN.Vaccine. 2024 Aug 13;42(20):126099. doi: 10.1016/j.vaccine.2024.06.066. Epub 2024 Jul 8.PMID: 38981743

Knowledge, attitude, and practice of Egyptian medical students towards healthcare workers' recommended vaccines: a nationwide cross-sectional survey.

Mohamed Shawqi M, El-Said YM, Behery MB, Abdelaziz A, Ibrahem ES, ElBoraie A, Khattab MA, Ghattas AS, Naeem A, Madany M, Elboraay T, Naguib MM, Allam AR, Allam AH, Bahbah AA, Ewis MI, Elsayed MA, Sherief L, KhallafAllah MT, Gouda MA, Aboshady OA.BMC Med Educ. 2024 Aug 14;24(1):876. doi: 10.1186/s12909-024-05712-8.PMID: 39143628

Integrated structural proteomics and machine learning-guided mapping of a highly protective precision vaccine against mycoplasma pulmonis.

Khan A, Ammar Zahid M, Farrukh F, Salah Abdelsalam S, Mohammad A, Al-Zoubi RM, Shkoor M, Ait Hssain A, Wei DQ, Agouni A.Int Immunopharmacol. 2024 Aug 16;141:112833. doi: 10.1016/j.intimp.2024.112833. Online ahead of print.PMID: 39153303

Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.

Benlarbi M, Ding S, Bélanger É, Tauzin A, Poujol R, Medjahed H, El Ferri O, Bo Y, Bourassa C, Hussin J, Fafard J, Pazgier M, Levade I, Abrams C, Côté M, Finzi A.mBio. 2024 Aug 14;15(8):e0090724. doi: 10.1128/mbio.00907-24. Epub 2024 Jul 2.PMID: 38953636

Predictors of COVID-19 vaccine uptake among youth with bipolar disorder spectrum disorders and their caregivers.

Keller VL, Klein CC, Wingler L, Blom TJ, Welge JA, Fornari VM, Higdon C, Crystal S, Patino LR, Correll CU, DelBello MP.J Affect Disord. 2024 Aug 13:S0165-0327(24)01277-1. doi: 10.1016/j.jad.2024.08.066. Online ahead of print.PMID: 39147152

Cytokine profile of anti-spike CD4⁺T cells predicts humoral and CD8⁺T cell responses after anti-SARS-CoV-2 mRNA vaccination.

Benhamouda N, Besbes A, Bauer R, Mabrouk N, Gadouas G, Desaint C, Chevrier L, Lefebvre M, Radenne A, Roelens M, Parfait B, Weiskopf D, Sette A, Gruel N, Courbebaisse M, Appay V, Paul S, Gorochov G, Ropers J, Lebbah S, Lelievre JD, Johannes L, Ulmer J, Lebeaux D, Friedlander G, De Lamballerie X, Ravel P, Kieny MP, Batteux F, Durier C, Launay O, Tartour E.iScience. 2024 Jul 2;27(8):110441. doi: 10.1016/j.isci.2024.110441. eCollection 2024 Aug 16.PMID: 39104410

The respiratory route of transmission of virulent polioviruses.

John TJ, Dharmapalan D, Steinglass R, Hirschhorn N.Infect Dis (Lond). 2024 Aug 20:1-7. doi: 10.1080/23744235.2024.2392791. Online ahead of print.PMID: 39163109

Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders.

Russ RK, Vandehei HM, Golovkina MI, Mogallapalli H, Caldera F, Hayney MS.Clin Infect Dis. 2024 Aug 16;79(2):562-563. doi: 10.1093/cid/ciae320.PMID: 38881506

Intranasal delivery of a recombinant adenovirus vaccine encoding the PEDV COE elicits potent mucosal and systemic antibody responses in mice.

Yan S, Luo Y, Zhan N, Xu H, Yao Y, Liu X, Dong X, Kang L, Zhang G, Liu P.Microbiol Spectr. 2024 Aug 15:e0069224. doi: 10.1128/spectrum.00692-24. Online ahead of print.PMID: 39145626

COVID-19 vaccination and involuntary movements: A longitudinal panel study.

Nielsen CM, Bech BH, Hansen SN, Jensen CB, Hansen KT, Nielsen H, Dantoft TM, Jørgensen T, Rask CU, Fink P, Thysen SM, Rytter D.J Neurol Sci. 2024 Aug 15;463:123136. doi: 10.1016/j.jns.2024.123136. Epub 2024 Jul 14.PMID: 39024744

Conceptualizing vaccine champions from an implementation science perspective: Findings from a national survey of primary care health professionals.

Kennedy KL, Gilkey MB, Queen TL, Heisler-MacKinnon JA, Hanson B, Kong WY, Brewington MK, Grabert BK.Prev Med. 2024 Aug 17:108104. doi: 10.1016/j.ypmed.2024.108104. Online ahead of print.PMID: 39159866

Crimean Congo hemorrhagic fever virus nucleoprotein and GP38 subunit vaccine combination prevents morbidity in mice.

Karaaslan E, Sorvillo TE, Scholte FEM, O'Neal TJ, Welch SR, Davies KA, Coleman-McCray JD, Harmon JR, Ritter JM, Pegan SD, Montgomery JM, Spengler JR, Spiropoulou CF, Bergeron É.NPJ Vaccines. 2024 Aug 14;9(1):148. doi: 10.1038/s41541-024-00931-y.PMID: 39143104

Vaccine strains of Rift Valley fever virus exhibit attenuation at the maternal-fetal placental interface.

McMillen CM, Megli C, Radisic R, Skvarca LB, Hoehl RM, Boyles DA, McGaughey JJ, Bird BH, McElroy AK, Hartman AL.J Virol. 2024 Aug 20;98(8):e0098324. doi: 10.1128/jvi.00983-24. Epub 2024 Jul 17.PMID: 39016561

Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus.

He Q, Chen Y, Li Y, Cheng X, Li X, Wu M, Wan J, Luo P, Wang Y, Gu J, Zhang Y.Vaccine. 2024 Aug 13;42(20):125976. doi: 10.1016/j.vaccine.2024.05.024. Epub 2024 May 31.PMID: 38824085

Indirect impact of childhood 13-valent pneumococcal conjugate vaccine (PCV13) in Canadian older adults: a Canadian Immunization Research Network (CIRN) retrospective observational study.

Nasreen S, Wang J, Marra F, Kwong JC, McGeer A, Sadarangani M, Wilson SE, Fadel SA.Thorax. 2024 Aug 19;79(9):861-869. doi: 10.1136/thorax-2023-220377.PMID: 38359926

Influences on COVID-19 vaccine Decision-Making: A Qualitative Study With Urban Indigenous and Rural Adults.

Peterson JC, Williams E, Goes-Ahead Lopez C, Jansen K, Albers AN, Newcomer SR, Caringi J.Community Health Equity Res Policy. 2024 Aug 16:2752535X241273816. doi: 10.1177/2752535X241273816. Online ahead of print.PMID: 39151928

Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis.

Wandera EA, Kurokawa N, Mutua MM, Muriithi B, Nyangao J, Khamadi SA, Kathiiko C, Wachira M, Njuguna E, Mwaura B, Golicha RO, Njau J, Morita K, Kaneko S, Komoto S, Tsutsui N, Ichinose Y.Vaccine. 2024 Aug 15;42(22):126210. doi: 10.1016/j.vaccine.2024.126210. Online ahead of print.PMID: 39151233

Three-year questionnaire study on human papillomavirus vaccination targeting new female college school students: Follow-up to a 2021 report to reveal the impact of a policy change in Japan.

Furuno A, Sukegawa A, Ohshige K, Suzuki Y, Yamaguchi M, Miyagi E, Ueda Y, Sekine M, Mizushima T.J

Chikungunya virus release is reduced by TIM-1 receptors through binding of envelope phosphatidylserine.

Reyes Ballista JM, Hoover AJ, Noble JT, Acciani MD, Miazgowicz KL, Harrison SA, Tabscott GAL, Duncan A, Barnes DN, Jimenez AR, Brindley MA.J Virol. 2024 Aug 20;98(8):e0077524. doi: 10.1128/jvi.00775-24. Epub 2024 Jul 15.PMID: 39007616

Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.

Gray P, Mariz FC, Eklund C, Eriksson T, Faust H, Kann H, Müller M, Paavonen J, Pimenoff VN, Sehr P, Surcel HM, Dillner J, Waterboer T, Lehtinen M.NPJ Vaccines. 2024 Aug 13;9(1):146. doi: 10.1038/s41541-024-00941-w.PMID: 39138224

The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.

Nakase T, Brownwright T, Okunromade O, Egwuenu A, Ogunbode O, Lawal B, Akanbi K, Grant G, Bassey OO, Coughlin MM, Bankamp B, Adetifa I, Metcalf CJE, Ferrari M.Vaccine. 2024 Aug 13;42(20):125982. doi: 10.1016/j.vaccine.2024.05.030. Epub 2024 May 29.PMID: 38811269

Multivariate analyses and machine learning link sex and age with antibody responses to SARS-CoV-2 and vaccination.

Cuperlovic-Culf M, Bennett SAL, Galipeau Y, McCluskie PS, Arnold C, Bagheri S, Cooper CL, Langlois MA, Fritz JH, Piccirillo CA, Crawley AM.iScience. 2024 Jul 10;27(8):110484. doi: 10.1016/j.isci.2024.110484. eCollection 2024 Aug 16.PMID: 39156648

No Yellow Fever Vaccine Reactions in IgE-Mediated Egg Allergic Patients.

Ramírez-Giraldo RH, Giraldo-Avila PA, Calle AM, Santamaria LC, Sánchez J.Int Arch Allergy Immunol. 2024 Aug 13:1-7. doi: 10.1159/000539505. Online ahead of print.PMID: 39137738

Immunogen characterization reveals an intrinsic hindrance in eliciting neutralizing antibodies against JN.1 variant.

Fan J, Zhang Y, Li S, Li Q, Zi Q, Mou X, Zheng J, Wang X, Guo X, Chen J, Yu J.iScience. 2024 Jun 28;27(8):110405. doi: 10.1016/j.isci.2024.110405. eCollection 2024 Aug 16.PMID: 39108735

Rational optimization of glycoprotein E (gE)-encoding mRNA for improved Varicella-zoster Virus mRNA vaccine development.

Huang L, Zhang S, Zhao T, Cai T, Bu L, Di Z, Zhang Y, Yang C, Yang Y, Lin A.Emerg Microbes Infect. 2024 Aug 13:2392661. doi: 10.1080/22221751.2024.2392661. Online ahead of print.PMID: 39137287

Prevalence of Health Misinformation on Social Media-Challenges and Mitigation Before, During, and Beyond the COVID-19 Pandemic: Scoping Literature Review.

Kbaier D, Kane A, McJury M, Kenny I.J Med Internet Res. 2024 Aug 19;26:e38786. doi: 10.2196/38786.PMID: 39159456

Vaccinating for My Family or for My Community? The Effect of Message Framing on Parental Intention to Vaccinate during the COVID Pandemic.

Wong CCY, Li LMW, Lee DKL, Lorez WP, Lo HYM.Int J Behav Med. 2024 Aug 13. doi: 10.1007/s12529-024-10313-2. Online ahead of print.PMID: 39138781

Advancement in the development of mRNA-based vaccines for respiratory viruses.

Troncoso-Bravo T, Ramírez MA, Loaiza RA, Román-Cárdenas C, Papazisis G, Garrido D, González PA, Bueno SM, Kalergis AM.Immunology. 2024 Aug 19. doi: 10.1111/imm.13844. Online ahead of print.PMID: 39161170

Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity.

Luo X, McAndrews KM, Arian KA, Morse SJ, Boeker V, Kumbhar SV, Hu Y, Mahadevan KK, Church KA, Chitta S, Ryujin NT, Hensel J, Dai J, Dowlatshahi DP, Sugimoto H, Kirtley ML, LeBleu VS, Shalapour S, Simmons JH, Kalluri R.J Control Release. 2024 Aug 13:S0168-3659(24)00556-X. doi: 10.1016/j.jconrel.2024.08.017. Online ahead of print.PMID: 39146981

Attitude towards cholera vaccination and its related factors in Jordan amid the 2022 Middle East outbreak.

Sallam M, Athamneh RY, Alkhazaleh R, Alzayadneh L, Jaradat L, Majali T, Obeidat S, Shhab A, Hallit S, Barakat M, Mahafzah A.BMC Public Health. 2024 Aug 16;24(1):2237. doi: 10.1186/s12889-024-19768-0.PMID: 39152391

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.

Chirenje ZM, Laher F, Dintwe O, Muyoyeta M, deCamp AC, He Z, Grunenberg N, Laher Omar F, Seaton KE, Polakowski L, Woodward Davis AS, Maganga L, Baden LR, Mayer K, Kalams S, Keefer M, Edupuganti S, Rodriguez B, Frank I, Scott H, Stranix-Chibanda L, Gurunathan S, Koutsoukos M, Van Der Meeren O, DiazGranados CA, Paez C, Andersen-Nissen E, Kublin J, Corey L, Ferrari G, Tomaras G, McElrath MJ.J Infect Dis. 2024 Aug 16;230(2):e405-e415. doi: 10.1093/infdis/jiad434.PMID: 37795976

Development of a fully automated chemiluminescent immunoassay for the quantitative and qualitative detection of antibodies against African swine fever virus p72.

Wang L, Li D, Zeng D, Wang S, Wu J, Liu Y, Peng G, Xu Z, Jia H, Song C.Microbiol Spectr. 2024 Aug 15:e0080924. doi: 10.1128/spectrum.00809-24. Online ahead of print.PMID: 39145655

Host-induced cell wall remodeling impairs opsonophagocytosis of *Staphylococcus aureus* by neutrophils.

Ledger EVK, Edwards AM.mBio. 2024 Aug 14;15(8):e0164324. doi: 10.1128/mbio.01643-24. Epub 2024 Jul 23.PMID: 39041819

Salmonella Biomapping of a Commercial Broiler Hatchery.

Rothrock MJ Jr, Al Hakeem WG, Oladeinde A, Looft T, Li X, Guard JY.J Food Prot. 2024 Aug 14:100347. doi: 10.1016/j.jfp.2024.100347. Online ahead of print.PMID: 39151796

Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina.

Guiñazú G, Dvorkin J, Mahmud S, Baral R, Pecenka C, Libster R, Clark A, Caballero MT.Vaccine. 2024 Aug 17;42(23):126234. doi: 10.1016/j.vaccine.2024.126234. Online ahead of print.PMID: 39154512

Disulfide-stabilized trimeric hemagglutinin ectodomains provide enhanced heterologous influenza protection.

Liu DJ, Zhong XQ, Ru YX, Zhao SL, Liu CC, Tang YB, Wu X, Zhang YS, Zhang HH, She JY, Wan MY, Li YW, Zheng HP, Deng L.Emerg Microbes Infect. 2024 Dec;13(1):2389095. doi: 10.1080/22221751.2024.2389095. Epub 2024 Aug 18.PMID: 39101691

Virus-like particles displaying the mature C-terminal domain of filamentous hemagglutinin are immunogenic and protective against *Bordetella pertussis* respiratory infection in mice.

Pyles GM, Huckaby AB, Gutierrez MdlP, Witt WT, Mateu-Borrás M, Dublin SR, Rocuskie-Marker C, Sesti BN, Peasak K, Bitzer GJ, Rader N, Weaver KL, Boehm DT, Fitzgerald N, Chapman J, Ulicny S, Damron FH, Barbier M.Infect Immun. 2024 Aug 13;92(8):e0027024. doi: 10.1128/iai.00270-24. Epub 2024 Jul 18.PMID: 39023271

Efficient and rapid one-step method to generate gene deletions in *Streptococcus pyogenes*.

Schiavolin L, Lakhloufi D, Botquin G, Deneubourg G, Bruyns C, Steinmetz J, Henrot C, Delforge V, Smeesters PR, Botteaux A.Microbiol Spectr. 2024 Aug 20:e0118524. doi: 10.1128/spectrum.01185-24. Online ahead of print.PMID: 39162539

Tumor targeting peptide TMTP1 modified Antigen capture Nano-vaccine combined with chemotherapy and PD-L1 blockade effectively inhibits growth of ovarian cancer.

Zhou Y, Wei R, Wang L, Li J, Wang W, Jiang G, Tan S, Li F, Wang X, Ma X, Xi L.J Nanobiotechnology. 2024 Aug 13;22(1):483. doi: 10.1186/s12951-024-02744-6.PMID: 39138475

Clinical outcomes and risk factors in patients with COVID-19 and autoimmune rheumatic diseases: insights from a major Australian hospital study.

Ling Z, Guy S, Fong C.Intern Med J. 2024 Aug 13. doi: 10.1111/imj.16488. Online ahead of print.PMID: 39136111

Module-combinatorial design and screening of multifunctional polymers based on polyaspartic acid for DNA delivery.

Xia Q, Jing Q, Lu C, Guo X, Chen X, Tang C, Han J, Wang H, Dong Y, Fang P, Zhang D, Teng X, Ren F.Int J Pharm. 2024 Aug 15;661:124350. doi: 10.1016/j.ijpharm.2024.124350. Epub 2024 Jun 15.PMID: 38885780

Modelling control strategies for pneumococcal meningitis outbreaks in the African meningitis belt.

Hadley L, Soeters HM, Cooper LV, Fernandez K, Latt A, Bita Fouda AA, Trotter C.Vaccine. 2024 Aug 13;42(20):125983. doi: 10.1016/j.vaccine.2024.05.031. Epub 2024 May 25.PMID: 38797628

Uptake among four indicated vaccines by adults aged 65 years and older in Japan, 2023.

Machida M, Fukushima S, Saitoh A, Inoue S, Tabuchi T.Vaccine. 2024 Aug 13;42(20):125985. doi: 10.1016/j.vaccine.2024.05.033. Epub 2024 May 21.PMID: 38772836

Landscape analysis of the Kenyan policy on the treatment and prevention of diarrheal disease among under-5 children.

Mberu B, Simiyu S, Gutema FD, Sewell D, Busienei PJ, Tumwebaze IK, Baker KK.BMJ Open. 2024 Aug 19;14(8):e081906. doi: 10.1136/bmjopen-2023-081906.PMID: 39160109

What Is the Economic Benefit of Annual COVID-19 Vaccination From the Adult Individual Perspective?

Bartsch SM, O'Shea KJ, Weatherwax C, Strych U, Velmurugan K, John DC, Bottazzi ME, Hussein M, Martinez MF, Chin KL, Ciciriello A, Heneghan J, Dibbs A, Scannell SA, Hotez PJ, Lee BY.J Infect Dis. 2024 Aug 16;230(2):382-393. doi: 10.1093/infdis/jiae179.PMID: 38581432

Mpox Discourse on Twitter by Sexual Minority Men and Gender-Diverse Individuals: Infodemiological Study Using BERTopic.

Wang Y, O'Connor K, Flores I, Berdahl CT, Urbanowicz RJ, Stevens R, Bauermeister JA, Gonzalez-Hernandez G.JMIR Public Health Surveill. 2024 Aug 13;10:e59193. doi: 10.2196/59193.PMID: 39137013

Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma.

Ramirez CA, Becker-Hapak M, Singhal K, Russler-Germain DA, Frenkel F, Barnell EK, McClain ED, Desai S, Schappe T, Onyeador OC, Kudryashova O, Belousov V, Bagaev A, Ocheredko E, Kiwala S, Hundal J, Skidmore ZL, Watkins MP, Mooney TB, Walker JR, Krysiak K, Gomez F, Fronick CC, Fulton RS, Schreiber RD, Mehta-Shah N, Cashen AF, Kahl BS, Ataullakhanov R, Bartlett NL, Griffith M, Griffith OL, Fehniger TA.Blood Adv. 2024 Aug 13;8(15):4035-4049. doi: 10.1182/bloodadvances.2022007792.PMID: 38713894

Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.

Mu Z, Whitley J, Martik D, Sutherland L, Newman A, Barr M, Parks R, Wiehe K, Cain DW, Hodges KZ, Venkatayogi S, Lee EM, Smith L, Mansouri K, Edwards RJ, Wang Y, Rountree W, Alameh M-G, Tam Y, Barbosa C, Tomai M, Lewis MG, Santrai S, Maughan M, Tian M, Alt FW, Weissman D, Saunders KO, Haynes BF.J Virol. 2024 Aug 13:e0013724. doi: 10.1128/jvi.00137-24. Online ahead of print.PMID: 39136461

A path forward for Staphylococcus aureus vaccine development.

Fritz SA, Bubeck Wardenburg J.J Exp Med. 2024 Oct 7;221(10):e20240002. doi: 10.1084/jem.20240002. Epub 2024 Aug 16.PMID: 39150449

Pertussis vaccine effectiveness following country-wide implementation of a hexavalent acellular pertussis immunization schedule in infants and children in Panama.

Calvo AE, Tristán Urrutia AG, Vargas-Zambrano JC, López Castillo H.Hum Vaccin Immunother. 2024 Dec 31;20(1):2389577. doi: 10.1080/21645515.2024.2389577. Epub 2024 Aug 20.PMID: 39164002

Variants in IGLL1 cause a broad phenotype from agammaglobulinemia to transient hypogammaglobulinemia.

Soomann M, Bily V, Elgizouli M, Kraemer D, Akgül G, von Bernuth H, Bloomfield M, Brodszki N, Candotti F, Förster-Waldl E, Freiberger T, Giżewska M, Klocperk A, Kölsch U, Nichols KE, Krüger R, Oak N, Pac M, Prader S, Schmiegelow K, Šedivá A, Sogkas G, Stittrich A, Stoltze UK, Theodoropoulou K, Wadt K, Wong M, Zeyda M, Schmid JP, Trück J.J Allergy Clin Immunol. 2024 Aug 13:S0091-6749(24)00819-4. doi: 10.1016/j.jaci.2024.08.002. Online ahead of print.PMID: 39147326

Signal peptide replacement of Ag43 enables an efficient bacterial cell surface display of receptor-binding domain of coronavirus.

Zhang X, Qin Y, Han X, Li Q, Wang Z, Wang X, Zhao L, Zhang H, Cai K, Chu Y, Gao C, Fan E.Biochem Biophys Res Commun. 2024 Aug 20;721:150146. doi: 10.1016/j.bbrc.2024.150146. Epub 2024 May 19.PMID: 38781660

Safety and immunogenicity of a next-generation live-attenuated yellow fever vaccine produced in a Vero cell line in the USA: a phase 1 randomised, observer-blind, active-controlled, dose-ranging clinical trial.

Modjarrad K, Scott PT, McCauley M, Ober-Shepherd B, Sondergaard E, Amare MF, Parikh AP, Omar B, Minutello AM, Adhikarla H, Wu Y, P AR, Delore V, Mantel N, Morrison MN, Kourbanova KS, Martinez ME, Guzman I, Greenleaf ME, Darden JM, Koren MA, Hamer MJ, Lee CE, Hutter JN, Peel SA, Robb ML, Vangelisti M, Feroldi E.Lancet Infect Dis. 2024 Aug 14:S1473-3099(24)00406-7. doi: 10.1016/S1473-3099(24)00406-7. Online ahead of print.PMID: 39153488

A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy.

Krishnan N, Priestman M, Uhía I, Charitakis N, Glegola-Madejska IT, Baer TM, Tranberg A, Faraj A, Simonsson US, Robertson BD.PLoS Biol. 2024 Aug 19;22(8):e3002766. doi: 10.1371/journal.pbio.3002766. Online ahead of print.PMID: 39159267

Trend, and multivariate decomposition of perinatal mortality in Ethiopia using further analysis of EDHS 2005-2016.

Agimas MC, Kefale D, Tesfie TK, Necho W, Munye T, Abeje G, Tesfahun Y, Simegn A, Kassaw A, Zeleke S, Demis S, Hailemeskel HS.BMC Pediatr. 2024 Aug 13;24(1):523. doi: 10.1186/s12887-024-04998-3.PMID: 39138454

Chemical synthesis and immunological evaluation of cancer vaccines based on ganglioside antigens and α-galactosylceramide.

Romanò C, Jiang H, Tahvili S, Wei P, Keiding UB, Clergeaud G, Skovbakke SL, Blomberg AL, Hafkenscheid L, Henriksen JR, Andresen TL, Goletz S, Hansen AE, Christensen D, Clausen MH.RSC Med Chem. 2024 Jun 21;15(8):2718-2728. doi: 10.1039/d4md00387j. eCollection 2024 Aug 14.PMID: 39149099

Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster.

Zhan BD, Song XD, Yu X, Yang GJ, Wan S, Ma MJ.Signal Transduct Target Ther. 2024 Aug 16;9(1):206. doi: 10.1038/s41392-024-01924-y.PMID: 39147762

Associations of CD4 Cell Count Measures With Infection-Related and Infection-Unrelated Cancer Risk Among People With HIV.

Nicolau IA, Moineddin R, Brooks JD, Antoniou T, Gillis JL, Kendall CE, Cooper C, Cotterchio M, Salters K, Smieja M, Kroch AE, Price C, Mohamed A, Burchell AN.J Acquir Immune Defic Syndr. 2024 Aug 15;96(5):447-456. doi: 10.1097/QAI.0000000000003452.PMID: 38985442

Neisserial adhesin A (NadA) binds human Siglec-5 and Siglec-14 with high affinity and promotes bacterial adhesion/invasion.

Benucci B, Spinello Z, Calvaresi V, Viviani V, Perrotta A, Faleri A, Utrio Lanfaloni S, Pansegrau W, d'Alterio L, Bartolini E, Pinzuti I, Sampieri K, Giordano A, Rappuoli R, Pizza M, Masignani V, Norais N, Maione D, Merola M.mBio. 2024 Aug 14;15(8):e0110724. doi: 10.1128/mbio.01107-24. Epub 2024 Jul 23.PMID: 39041817

Reply to: combined systemic and intralesional 9-valent human papillomavirus vaccine for recurrent squamous cell carcinoma in situ of the penis.

Kravvas G, Haider A, Watchorn RE, Bunker C.Int J Dermatol. 2024 Aug 14. doi: 10.1111/ijd.17443. Online ahead of print.PMID: 39143685

Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia.

Ng'ombe H, Bosomprah S, Phiri B, Muchimba M, Liswaniso F, Chibuye M, Luchen CC, Chibesa K, Musukuma-Chifulo K, Mwape K, Tigere S, Silwamba S, Sinkala A, Simuyandi M, Mbewe N, Kapaya F, Cunningham AF, Chilengi R, Sack D, Chisenga CC.Vaccine. 2024 Aug 13;42(20):125979. doi: 10.1016/j.vaccine.2024.05.027. Epub 2024 May 17.PMID: 38760271

An evaluation of a multi-partner approach to increase routine immunization coverage in six northern Nigerian States.

Dougherty L, Adediran M, Akinola A, Alabi M, Etim EO, Ohioghame J, Adedimeji A.BMC Health Serv Res. 2024 Aug 20;24(1):951. doi: 10.1186/s12913-024-11403-3.PMID: 39164689

A Multiseason Randomized Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants With Chronic Disease or Older Age.

Sajkov D, Woodman R, Honda-Okubo Y, Barbara J, Chew D, Toson B, Petrovsky N.J Infect Dis. 2024 Aug 16;230(2):444-454. doi: 10.1093/infdis/jiad589.PMID: 38157402

Field Effectiveness of a Typhoid Conjugate Vaccine: The 2018 Navi Mumbai Pediatric TCV Campaign.

Date K, LeBoa C, Hoffman SA, Haldar P, Harvey P, An Q, Zhang C, Yewale VN, Daruwalla S, Dharmapalan D, Gavhane J, Joshi S, Rai R, Rathod V, Shetty K, Warrier DS, Yadav S, Shimpi R, Jayaprasad N, Horng L, Fagerli K, Borhade P, Chakraborty D, Katkar A, Kunwar A, Andrews JR, Bahl S, Bhatnagar P, Dutta S, Luby SP.Am J Trop Med Hyg. 2024 Aug 13:tpmd240181. doi: 10.4269/ajtmh.24-0181. Online ahead of print.PMID: 39137766

Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study.

Jameie M, Azizmohammad Looha M, Ebadi Z, Amanollahi M, Amani K, Nobahari F, Abdollahi A, Mousavi M, Pourghaz B, Harirchian MH.BMC Neurol. 2024 Aug 20;24(1):291. doi: 10.1186/s12883-024-03793-y.PMID: 39164636

Treponema pallidum Periplasmic and Membrane Proteins Are Recognized by Circulating and Skin CD4+ T Cells.

Reid TB, Godornes C, Campbell VL, Laing KJ, Tantalo LC, Gomez A, Pholsena TN, Lieberman NAP, Krause TM, Cegielski VI, Culver LA, Nguyen N, Tong DQ, Hawley KL, Greninger AL, Giacani L, Cameron CE, Dombrowski JC, Wald A, Koelle DM.J Infect Dis. 2024 Aug 16;230(2):281-292. doi: 10.1093/infdis/jiae245.PMID: 38932740

The Raf kinase inhibitors Dabrafenib and Regorafenib impair Zika virus replication via distinct mechanisms.

Wilken L, Rimmelzwaan GF, Elbahesh H.J Virol. 2024 Aug 20;98(8):e0061824. doi: 10.1128/jvi.00618-24. Epub 2024 Jul 18.PMID: 39023323

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024.

Britton A, Roper LE, Kotton CN, Hutton DW, Fleming-Dutra KE, Godfrey M, Ortega-Sanchez IR, Broder KR, Talbot HK, Long SS, Havers FP, Melgar M.MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):696-702. doi: 10.15585/mmwr.mm7332e1.PMID: 39146277

Resilience throughout COVID-19: Unmasking the realities of COVID-19 and vaccination facilitators, barriers, and attitudes among Black Canadians.

Ezezika O, Adedugbe T, Jonas I, Mengistu M, Graham T, Girmay B, Thullah Y, Thompson C.PLoS One. 2024 Aug 20;19(8):e0304904. doi: 10.1371/journal.pone.0304904. eCollection 2024.PMID: 39163295

Corrigendum to "Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine" [Int. Immunopharmacol. 131 (2024) 111817].

Yu X, Min H, Yao S, Yao G, Zhang D, Zhang B, Chen M, Liu F, Cui L, Zheng L, Cao Y.Int Immunopharmacol. 2024 Aug 20;137:112260. doi: 10.1016/j.intimp.2024.112260. Epub 2024 Jun 25.PMID: 38926073

Utilization of novel molecular multiplex methods for the detection and, epidemiological surveillance of dengue virus serotypes and chikungunya virus in Burkina Faso, West Africa.

Gomgnimbou MK, Belem LRW, Some K, Diallo M, Barro B, Kaboré A, Hafalla JCR, Sangaré I.Mol Biol Rep. 2024 Aug 14;51(1):906. doi: 10.1007/s11033-024-09847-1.PMID: 39141163

Bacterial Extracellular Vesicles: Potential Therapeutic Applications, Challenges, and Future Prospects.

Humaira, Ahmad I, Shakir HA, Khan M, Franco M, Irfan M.J Basic Microbiol. 2024 Aug 15:e2400221. doi: 10.1002/jobm.202400221. Online ahead of print.PMID: 39148315

Development of an indirect ELISA for detecting Toxoplasma gondii IgG antibodies based on a recombinant TgIMP1 protein.

Dong H, Zhang J, Wang Q, Shen Y, Zhou B, Dai L, Zhu W, Sun H, Xie X, Xie H, Xu C, Zhao G, Yin K.PLoS Negl Trop Dis. 2024 Aug 14;18(8):e0012421. doi: 10.1371/journal.pntd.0012421. Online ahead of print.PMID: 39141677

Japanese encephalitis virus NS5 protein interacts with nucleolin to enhance the virus replication.

Deb A, Nagpal S, Yadav RK, Thakur H, Nair D, Krishnan V, Vrati S.J Virol. 2024 Aug 20;98(8):e0085824. doi: 10.1128/jvi.00858-24. Epub 2024 Jul 30.PMID: 39078257

Tumor-Associated Antigen Burden Correlates with Immune Checkpoint Blockade Benefit in Tumors with Low Levels of T-cell Exhaustion.

Wang Y, Hu M, Finn OJ, Wang XS.Cancer Immunol Res. 2024 Aug 13. doi: 10.1158/2326-6066.CIR-23-0932. Online ahead of print.PMID: 39137006

Correction to: Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.

[No authors listed]J Infect Dis. 2024 Aug 16;230(2):e503. doi: 10.1093/infdis/jiae334.PMID: 38949967

Repeated vaccination does not appear to significantly weaken the protective effect of influenza vaccine in the elderly: A test-negative case-control study in China.

Yang T, Tong F, Tang L, Li P, Li B, Ye L, Zhou J.Vaccine. 2024 Aug 13;42(20):125986. doi: 10.1016/j.vaccine.2024.05.034. Epub 2024 May 18.PMID: 38762359

Effectiveness of momentary intervention on influenza vaccination among the elderly in China: From willingness to action.

Zhang WX, Zhang Y, Du J, Shi W, Zhang SS, Yuan M, Zhou Y, Wang L, Zhao TS, Ma Q, Cai X, Zhang S, Yang H, Zhang X, Wang M, Huang N, Zeng J, Liu Y, Wu J, Cui F, Lu QB.Vaccine. 2024 Aug 13;42(20):125984. doi: 10.1016/j.vaccine.2024.05.032. Epub 2024 May 22.PMID: 38777696

Enhancing Immune Responses against SARS-CoV-2 Variants in Aged Mice with INDUK: A Chimeric DNA Vaccine Encoding the Spike S1-TM Subunits.

Cui L, Wang J, Orlando F, Giacconi R, Malavolta M, Bartozzi B, Galeazzi R, Giorgini G, Pesce L, Cardarelli F, Quagliarini E, Renzi S, Xiao S, Pozzi D, Provinciali M, Caracciolo G, Marchini C, Amici A.ACS Omega. 2024 Jul 30;9(32):34624-34635. doi: 10.1021/acsomega.4c03285. eCollection 2024 Aug 13.PMID: 39157118

The N and C-terminal deleted variant of the dengue virus NS1 protein is a potential candidate for dengue vaccine development.

Nasar S, Iftikhar S, Saleem R, Nadeem MS, Ali M.Sci Rep. 2024 Aug 14;14(1):18883. doi: 10.1038/s41598-024-65593-1.PMID: 39143088

Respiratory illness in young and adult cattle caused by bovine viral diarrhea virus subgenotype 2b in singular and mixed bacterial infection in a BVDV-vaccinated dairy herd.

Fritzen JTT, Yasumitsu CY, Silva IV, Lorenzetti E, Alfieri AF, Alfieri AA.Braz J Microbiol. 2024 Aug 15. doi: 10.1007/s42770-024-01476-x. Online ahead of print.PMID: 39143403

Delivery of *Yersinia pestis* antigens via *Escherichia coli* outer membrane vesicles offered improved protection against plague.

Tong Z, Zhang X, Guo X, Wu G, Cao S, Zhang Y, Meng X, Wang T, Wang Y, Song Y, Yang R, Du Z.mSphere. 2024 Aug 19:e0033024. doi: 10.1128/msphere.00330-24. Online ahead of print.PMID: 39158304

Streptococcus pneumoniae carriage, serotypes, genotypes, and antimicrobial resistance trends among children in Portugal, after introduction of PCV13 in National Immunization Program: A cross-sectional study.

Candeias C, Almeida ST, Paulo AC, Simões AS, Ferreira B, Cruz AR, Queirós M, Touret T, Brito-Avô A, de Lencastre H, Sá-Leão R.Vaccine. 2024 Aug 14;42(22):126219. doi: 10.1016/j.vaccine.2024.126219. Online ahead of print.PMID: 39146858

Serial cell culture passaging *in vitro* led to complete attenuation and changes in the characteristic features of a virulent porcine deltacoronavirus strain.

Zhang L, Yu R, Wang L, Zhang Z, Lu Y, Zhou P, Wang Y, Guo H, Pan L, Liu X.J Virol. 2024 Aug 20;98(8):e0064524. doi: 10.1128/jvi.00645-24. Epub 2024 Jul 16.PMID: 39012141

Collective Sensemaking and Healthcare Workers' Ripple Effect Influencing Vaccine Hesitancy in West Michigan.

Hedges K, Willson M.Med Anthropol. 2024 Aug 14:1-16. doi: 10.1080/01459740.2024.2388199. Online ahead of print.PMID: 39141891

Charge Detection Mass Spectrometry Reveals Favored Structures in the Assembly of Virus-Like Particles: Polymorphism in Norovirus GI.1.

Miller LM, Draper BE, Wang JC, Jarrold MF.Anal Chem. 2024 Aug 13;96(32):13150-13157. doi: 10.1021/acs.analchem.4c01913. Epub 2024 Jul 29.PMID: 39074122

The public health and economic burden of long COVID in Australia, 2022-24: a modelling study.

Costantino V, Grafton Q, Kompas T, Chu L, Honeyman D, Notaras A, MacIntyre CR.Med J Aust. 2024 Aug 19;221(4):217-223. doi: 10.5694/mja2.52400.PMID: 39154292

Developing a roadmap to reach and sustain 90% full immunization coverage through a cross-sectoral system strengthening strategy in Bihar, India.

Ratna M, Singh SK, Sinha NK, Kannure M, Bhatia M, Aggarwal MK, Dalpath SK, Sharma S, Shah V.BMC Health Serv Res. 2024 Aug 14;24(1):933. doi: 10.1186/s12913-024-11380-7.PMID: 39143542

Immunogenicity of trivalent DNA vaccine candidate encapsulated in Chitosan-TPP nanoparticles against EV-A71 and CV-A16.

Yew JS, Ong SK, Lim HX, Tan SH, Ong KC, Wong KT, Poh CL.Nanomedicine (Lond). 2024 Aug 14:1-21. doi: 10.1080/17435889.2024.2372243. Online ahead of print.PMID: 39140594

Exploring factors influencing awareness and knowledge of human papillomavirus in Chinese college students: A cross-sectional study.

Chen X, Xu T, Wu J, Sun C, Han X, Wang D, Zhang Z, Qiao C, Tao X.Hum Vaccin Immunother. 2024 Dec 31;20(1):2388347. doi: 10.1080/21645515.2024.2388347. Epub 2024 Aug 14.PMID: 39140222

Oral supplementation with postbiotics modulates the immune response produced by myxomatosis vaccination in wild rabbits.

García-Vicente EJ, Rey-Casero I, Martín M, Pérez A, Benito-Murcia M, Risco D.Vaccine. 2024 Aug 13;42(20):125978. doi: 10.1016/j.vaccine.2024.05.026. Epub 2024 May 17.PMID: 38760270

Evaluation of the protective effect of the intranasal vaccines adjuvanted with bacterium-like particles against intestinal infection.

Tsujii A, Takahashi K, Harada H, Kawashima S, Oikawa H, Fukushima H, Hayakawa Y, Koizumi J, Inoue N, Koshizuka T.Vaccine. 2024 Aug 13;42(20):125975. doi: 10.1016/j.vaccine.2024.05.023. Epub 2024 May 19.PMID: 38763852

Identification of a Spike-Specific CD8+ T-Cell Epitope Following Vaccination Against the Middle East Respiratory Syndrome Coronavirus in Humans.

Harrer CE, Mayer L, Fathi A, Lassen S, Ly ML, Zinser ME, Wolf T, Becker S, Sutter G, Dahlke C, Addo MM; MVA-MERS-S Study Group.J Infect Dis. 2024 Aug 16;230(2):e327-e332. doi: 10.1093/infdis/jiad612.PMID: 38195212

Development of a high-performance liquid chromatography using rhodamine B hydrazide as the derivatization reagent for determination of β propiolactone residues in inactivated COVID-19 vaccines.

Zohreh Mirjalili S, Chavoshi F, Amini M, ZahraTamiji, Kobarfard F, Shirangi M.J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Aug 15;1244:124241. doi: 10.1016/j.jchromb.2024.124241. Epub 2024 Jul 15.PMID: 39053110

An efficient *in vivo*-inducible CRISPR interference system for group A *Streptococcus* genetic analysis and pathogenesis studies.

Bjånes E, Stream A, Janssen AB, Gibson PS, Bravo AM, Dahesh S, Baker JL, Varble A, Nizet V, Veening J-W.mBio. 2024 Aug 14;15(8):e0084024. doi: 10.1128/mbio.00840-24. Epub 2024 Jul 2.PMID: 38953375

Scoping Review of Pediatric Primary Care Educational Literature.

Bruton L, Nunes D, Quadri M.Clin Pediatr (Phila). 2024 Aug 19:99228241274905. doi: 10.1177/00099228241274905. Online ahead of print.PMID: 39158507

cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B.

Naully PG, Tan MI, Agustiningsih A, Sukowati C, Giri-Rachman EA.Ann Hepatol. 2024 Aug 13:101533. doi: 10.1016/j.aohep.2024.101533. Online ahead of print.PMID: 39147134

Immune gene expression changes more during a malaria transmission season than between consecutive seasons.

Tebben K, Yirampo S, Coulibaly D, Koné AK, Laurens MB, Stucke EM, Dembélé A, Tolo Y, Traoré K, Niangaly A, Berry AA, Kouriba B, Plowe CV, Doumbo OK, Lyke KE, Takala-Harrison S, Thera MA, Travassos MA, Serre D.Microbiol Spectr. 2024 Aug 20:e0096024. doi: 10.1128/spectrum.00960-24. Online ahead of print.PMID: 39162546

Inhibition of Giardia duodenalis by isocryptolepine -triazole adducts and derivatives.

Popruk S, Tummatorn J, Sreesai S, Ampawong S, Thiangtrongjit T, Tipthara P, Tarning J, Thongsornkleeb C, Ruchirawat S, Reamtong O.Int J Parasitol Drugs Drug Resist. 2024 Aug 13;26:100561. doi: 10.1016/j.ijpddr.2024.100561. Online ahead of print.PMID: 39151240

Novel intervention based on an individualized bundle of care to decrease infection in kidney transplant recipients.

de Jorge-Huerta L, Silva JT, Fernández-Ruiz M, Rodríguez-Goncer I, Pérez-Jacoiste Asín MA, Ruiz-Merlo T, Heredia-Mena C, González-Monte E, Polanco N, San Juan R, Andrés A, Aguado JM, López-Medrano F.Transpl Infect Dis. 2024 Aug 13:e14354. doi: 10.1111/tid.14354. Online ahead of print.PMID: 39136146

Microbiota-driven vaccination in soft ticks: Implications for survival, fitness and reproductive capabilities in Ornithodoros moubata.

Cano-Argüelles AL, Piloto-Sardiñas E, Maitre A, Mateos-Hernández L, Maye J, Wu-Chuang A, Abuin-Denis L, Obregón D, Bamgbose T, Oleaga A, Cabezas-Cruz A, Pérez-Sánchez R.Mol Ecol. 2024 Aug 19:e17506. doi: 10.1111/mec.17506. Online ahead of print.PMID: 39161118

Eosinophils as Modulators of Host Defense during Parasitic, Fungal, Bacterial, and Viral Infections.

Gazzinelli-Guimaraes PH, Jones SM, Voehringer D, Mayer-Barber KD, Samarasinghe AE.J Leukoc Biol. 2024 Aug 13:qiae173. doi: 10.1093/jleuko/qiae173. Online ahead of print.PMID: 39136237

Sulfate Radical Based In Situ Vaccine Boosts Systemic Antitumor Immunity via Concurrent Activation of Necroptosis and STING Pathway.

Huang Y, Zou J, Huo J, Zhang M, Yang Y.Adv Mater. 2024 Aug 15:e2407914. doi: 10.1002/adma.202407914. Online ahead of print.PMID: 39148154

Color-Tunable $CsCdCl_3$ Perovskite for Low-Temperature Anticounterfeiting and Information Storage Applications.

Hao X, Wang T, Zhu X, Hou L, Nie L, Liu H, Yue Y, An X, He Q, Yu X.Inorg Chem. 2024 Aug 13. doi: 10.1021/acs.inorgchem.4c02629. Online ahead of print.PMID: 39138609

Detection and comparison of SARS-CoV-2 antibody produced in naturally infected patients and vaccinated individuals in Addis Ababa, Ethiopia: multicenter cross-sectional study.

Bashea C, Gize A, Lejisa T, Bikila D, Zerihun B, Challa F, Melese D, Gebreyohanns A, Gorems K, Ali S, Hundie GB, Tola HH, Tsegaye W.Virol J. 2024 Aug 19;21(1):192. doi: 10.1186/s12985-024-02443-6.PMID: 39160532

In vitro-irradiated cancer vaccine enhances anti-tumor efficacy of radiotherapy and PD-L1 blockade in a syngeneic murine breast cancer model.

Kim Y, Hyuck Jeon S, Kim S, Hyun Kang M, Guk Han M, Yup Lee S, Ah Kim I.Radiother Oncol. 2024 Aug 17:110480. doi: 10.1016/j.radonc.2024.110480. Online ahead of print.PMID: 39159681

Influenza vaccination stimulates maturation of the human T follicular helper cell response.

Schattgen SA, Turner JS, Ghonim MA, Crawford JC, Schmitz AJ, Kim H, Zhou JQ, Awad W, Mettelman RC, Kim W, McIntire KM, Haile A, Klebert MK, Suessen T, Middleton WD, Teefey SA, Presti RM, Ellebedy AH, Thomas PG.Nat Immunol. 2024 Aug 20. doi: 10.1038/s41590-024-01926-6. Online ahead of print.PMID: 39164477

Specific antibody responses to Qβ-displayed Plasmodium falciparum-derived UB05 and MSP3 proteins in mother-neonate couples.

Lissom A, Megnekou R, Tchouangueu TF, Ngu L, Djontu JC, Ouambo HF, Sanders C, Tchadji JC, Sake CS, Tchuandom SB, Bawage S, Okoli AS, Park CG, Waffo AB, Godwin NW.Scand J Immunol. 2024 Aug 19:e13404. doi: 10.1111/sji.13404. Online ahead of print.PMID: 39155843

Risk of Relapse After COVID-19 Vaccination Among Patients With Multiple Sclerosis in France: A Self-Controlled Case Series.

Moisset X, Leray E, Chenaf C, Taithe F, Vukusic S, Mulliez A, Clavelou P.Neurology. 2024 Sep 10;103(5):e209662. doi: 10.1212/WNL.0000000000209662. Epub 2024 Aug 14.PMID: 39141880

Evaluation of the safety, immunogenicity and protective effect of an attenuated Pseudomonas plecoglossicida strain deltagacS as the live vaccine for the large yellow croaker (Larimichthys crocea).

Kang TJ, Zhou SM, Xie X, Ma RR, Qian D, Jin S, Yin F.Fish Shellfish Immunol. 2024 Aug 13:109836. doi: 10.1016/j.fsi.2024.109836. Online ahead of print.PMID: 39147177

First Nationwide Mpox Vaccination Program in the Republic of Korea: Implications for an Enhanced Public Health Response.

Kwon SL, Song M, Lee W, Shin J, Lee SY, Yeo SG, Kim M, Jeong S, Park J, Lee D, Lim S.J Korean Med Sci. 2024 Aug 19;39(32):e235. doi: 10.3346/jkms.2024.39.e235.PMID: 39164057

Evaluating Zindagi Mehfooz- Electronic Immunization Registry and suite of digital health interventions to improve the coverage and timeliness of immunization services : A mixed methods study in Sindh, Pakistan.

Mechael P, Gilani S, Ahmed A, LeFevre A, Mohan D, Memon A, Shah MT, Siddiqi DA, Chandir S, Soundardjee R.J Med Internet Res. 2024 Aug 20. doi: 10.2196/52792. Online ahead of print.PMID: 39162666

Improved cellular immune response induced by intranasal boost immunization with chitosan coated DNA vaccine against H9N2 influenza virus challenge.

Zhang T, Tian Y, Zhang X, Wang W, He Y, Ge C, Jia F, Wang Z, Jiang Y.Microb Pathog. 2024 Aug 18:106871. doi: 10.1016/j.micpath.2024.106871. Online ahead of print.PMID: 39163919

The impact of the COVID-19 pandemic on UK parents' attitudes towards routine childhood vaccines: A mixed-methods study.

Skirrow H, Lewis C, Haque H, Choundary-Salter L, Foley K, Whittaker E, Costelloe C, Bedford H, Saxena S.PLoS One. 2024 Aug 13;19(8):e0306484. doi: 10.1371/journal.pone.0306484. eCollection 2024.PMID: 39137199

Immunological correlates of protection mediated by a whole organism, Cryptococcus neoformans, vaccine deficient in chitosan.

Specht CA, Wang R, Oliveira LVN, Hester MM, Gomez C, Mou Z, Carlson D, Lee CK, Hole CR, Lam WC, Upadhya R, Lodge JK, Levitz SM.mBio. 2024 Aug 14;15(8):e0174624. doi: 10.1128/mbio.01746-24. Epub 2024 Jul 9.PMID: 38980038

Bluetongue virus serotype 3 in ruminants in the Netherlands: Clinical signs, seroprevalence and pathological findings.

van den Brink KMJA, Santman-Berends IMGA, Harkema L, Scherpenzeel CGM, Dijkstra E, Bisschop PIH, Peterson K, van de Burgwal NS, Waldeck HWF, Dijkstra T, Holwerda M, Spierenburg MAH, van den Brom R.Vet Rec. 2024 Aug 17;195(4):e4533. doi: 10.1002/vetr.4533. Epub 2024 Aug 15.PMID: 39148262

How to prevent rubella epidemics and congenital rubella syndrome: lessons from 42 years of longitudinal epidemiology in Osaka Prefecture, Japan (1982-2023).

Kanbayashi D, Kurata T, Kaida Y, Miyoshi T, Okayama F, Kase T, Komano J, Takahashi K, Ikuta K, Motomura K.J Infect Dis. 2024 Aug 14:jiae402. doi: 10.1093/infdis/jiae402. Online ahead of print.PMID: 39141594

Characterization of the SARS-CoV-2 antibody landscape in Norway in the late summer of 2022: high seroprevalence in all age groups with patterns of primary Omicron infection in children and hybrid immunity in adults.

Tunheim G, Fossum E, Robertson AH, Rø GØI, Chopra A, Vaage JT, Vikse EL, Kran AB, Magnus P, Trogstad L, Mjaaland S, Hungnes O, Lund-Johansen F.BMC Infect Dis. 2024 Aug 20;24(1):841. doi: 10.1186/s12879-024-09670-w.PMID: 39164637

Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.

Palazzo L, Lindblom J, Kihlgren Olsson E, Nikiphorou E, Wincup C, Saha S, Shaharir SS, Katchamart W, Akarawatcharangura Goo P, Traboco L, Chen YM, Lilleker JB, Nune A, Pauling JD, Agarwal V, Dzifa D, Toro

Gutiérrez CE, Caballero-Uribe CV, Chinoy H; COVAD Study Group; Agarwal V, Gupta L, Parodis I.Rheumatol Int. 2024 Aug 13. doi: 10.1007/s00296-024-05682-6. Online ahead of print.PMID: 39138675

A multi-targeting immunotherapy ameliorates multiple facets of Alzheimer's disease in 3xTg mice.

Feng X, Hou Y, Liu J, Yan F, Dai M, Chen M, Wang J, Li J, Liu Z, Sun D, Zhang Y, Yu X, Kong W, Wu H.NPJ Vaccines. 2024 Aug 20;9(1):153. doi: 10.1038/s41541-024-00942-9.PMID: 39164276

Establishment and identification of the head kidney cell line of yellowfin seabream (Acanthopagrus latus) and its application in a virus susceptibility study.

Yang HY, Zhu KC, Guo HY, Zhang N, Liu BS, Xian L, Zhu TF, Guo R, Zhang DC.Dev Comp Immunol. 2024 Aug 13;161:105243. doi: 10.1016/j.dci.2024.105243. Online ahead of print.PMID: 39147080

Combining Killed Vaccine Candidate with Different Adjuvants to Determine Prophylactic Potential against Leishmaniasis.

Kelleci K, Allahverdiyev A, Bağırova M, Ihlamur M, Abamor EŞ.Acta Parasitol. 2024 Aug 20. doi: 10.1007/s11686-024-00903-1. Online ahead of print.PMID: 39164549

The Effect of COVID-19 Vaccination on Outpatient Antibiotic Prescribing in Older Adults: A Self-Controlled Risk-Interval Study.

Jorgensen SCJ, Brown K, Clarke AE, Schwartz KL, Maxwell C, Daneman N, Kwong JC, MacFadden DR.Clin Infect Dis. 2024 Aug 16;79(2):375-381. doi: 10.1093/cid/ciae182.PMID: 38700036

A Prospective Study of the Relationship of COVID-19 Vaccination to Menstrual Cycle Characteristics in Adolescent Girls.

Payne LA, Seidman LC, Granger SW, Edelman A, Ren B.J Adolesc Health. 2024 Aug 15:S1054-139X(24)00307-0. doi: 10.1016/j.jadohealth.2024.06.023. Online ahead of print.PMID: 39152975

Population immunity to varicella in Canada: A Canadian Immunization Research Network (CIRN) study.

Wright J, Crowcroft N, McLachlan E, Perez-Iratxeta C, Joh E, Osman S, Hatchette T, Deeks SL, Wilson SE, Hughes SL, Halperin SA, Buchan SA, Ward BJ, Gubbay J, Brisson M, Serhir B, Severini A, Bolotin S.PLoS One. 2024 Aug 19;19(8):e0309154. doi: 10.1371/journal.pone.0309154. eCollection 2024.PMID: 39159217

The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation.

Borrego B, Alonso C, Moreno S, de la Losa N, Sánchez-Cordón PJ, Brun A.PLoS Negl Trop Dis. 2024 Aug 19;18(8):e0012011. doi: 10.1371/journal.pntd.0012011. Online ahead of print.PMID: 39159263

Memory B cell responses induced by pneumococcal conjugate vaccine schedules with fewer doses: analysis of a randomised-controlled trial in Viet Nam.

Ong DS, Phan TV, Temple B, Toh ZQ, Nguyen CD, Vientrung K, Nguyen HVA, Thi Trang Dai V, Bright K, Tran HP, Higgins RA, Cheung YB, Vu Nguyen T, Mulholland K, Licciardi PV.Nat Commun. 2024 Aug 14;15(1):6968. doi: 10.1038/s41467-024-51413-7.PMID: 39138203

The desire of autonomy: A lever for vaccination of the elderly? Results of a qualitative study.

Addario A, Pardo M, Gavazzi G, Bongue B, Célarier T, Dorier S, Barth N, Botelho-Nevers E.Hum Vaccin Immunother. 2024 Dec 31;20(1):2390227. doi: 10.1080/21645515.2024.2390227. Epub 2024 Aug 19.PMID: 39161121

Detection and genomic characterization of an avian influenza virus A/mute swan/Mangystau/1-S24R-2/2024 (H5N1; clade 2.3.4.4b) strain isolated from the lung of a dead swan in Kazakhstan.

Tabynov K, Strochkov V, Sandybayev N, Karibayev T, Berdikulov M, Yelchibayeva L, Zharmambet K, Kuanyshbek A, Zhumadilova Z, Tabynov K.Microbiol Resour Announc. 2024 Aug 13;13(8):e0026024. doi: 10.1128/mra.00260-24. Epub 2024 Jul 22.PMID: 39037308

Engineered bacterial membrane vesicle as safe and efficient nano-heaters to reprogram tumor microenvironment for enhanced immunotherapy.

Liu K, Du S, Yang J, Li J, Wang S, Zhang Z, Luo W, Chen C, Yang J, Han X.J Control Release. 2024 Aug 13;374:127-139. doi: 10.1016/j.jconrel.2024.08.008. Online ahead of print.PMID: 39122216

Public health management of invasive meningococcal disease outbreaks: worldwide 1973-2018, a systematic review.

Morello BR, Milazzo A, Marshall HS, Giles LC.BMC Public Health. 2024 Aug 20;24(1):2254. doi: 10.1186/s12889-024-19740-y.PMID: 39164680

Multicentre case-control study of pneumococcal infections among children with pneumonia in Peninsular Malaysia (MY-Pneumo): a study protocol.

Ramzi NH, Hoong ATC, Johari NA, Nathan AM, Teh CSJ, Sulaiman NA, Ilias MI, Deris ZZ, Hazlan SNH, Nasir NSM, Bakar AA, Helmi MAM, Juhari WKW, Kamarudin N, Chong CW, Cleary DW, Clarke SC, Sulaiman LH.BMC Public Health. 2024 Aug 20;24(1):2255. doi: 10.1186/s12889-024-19789-9.PMID: 39164673

A novel Candida albicans Als3, Hwp1 and Met6 derived complex peptide protects mice against hematogenously induced candidiasis.

Diez A, Arrieta-Aguirre I, Carrano G, Fernandez-de-Larrinoa I, Moragues MD.Vaccine. 2024 Aug 13;42(20):125990. doi: 10.1016/j.vaccine.2024.05.038. Epub 2024 May 23.PMID: 38789371

Lipo-pam adjuvanted herpes zoster vaccine induces potent gE-specific cellular and humoral immune responses.

Jeong SK, Ham SJ, Baek SH, Jung EJ, Jo HJ, Cha HR, Lee JM, Ahn BC, Yum JS, Chun E.NPJ Vaccines. 2024 Aug 17;9(1):150. doi: 10.1038/s41541-024-00939-4.PMID: 39154056

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Kabirian R, Tredan O, Marmé F, Paoletti X, Eberst L, Lebreton C, La Motte Rouge T, Sabatier R, Angelergues A, Fabbro M, Gorp TV, Mansi L, Gladieff L, Kaczmarek E, Alexandre J, Grellety T, Favier L,

Welz J, Frenel JS, Leary A.Future Oncol. 2024 Aug 19:1-10. doi: 10.1080/14796694.2024.2386922. Online ahead of print.PMID: 39155847

A vaccine programme comprising GA08 (GI-27) and Mass (GI-1) strains prevents DMV1639 (GI-17) infectious bronchitis virus transmission among broiler chickens.

Brimer SK, Fischer EAJ, Beckstead R, White J, Cazaban C, Tatár-Kis T, Velkers FC, Elattrache J, Stegeman A.Avian Pathol. 2024 Aug 16:1-13. doi: 10.1080/03079457.2024.2383765. Online ahead of print.PMID: 39045705

MicroRNA levels in patients with chronic hepatitis B virus and HIV coinfection in a high-prevalence setting; KwaZulu-Natal, South Africa.

Mthethwa L, Parboosing R, Msomi N.BMC Infect Dis. 2024 Aug 16;24(1):833. doi: 10.1186/s12879-024-09715-0.PMID: 39148016

Epigenetic programming of host lipid metabolism associated with resistance to TST/IGRA conversion after exposure to *Mycobacterium tuberculosis*.

Dill-McFarland KA, Simmons JD, Peterson GJ, Nguyen FK, Campo M, Benchek P, Stein CM, Vaisar T, Mayanja-Kizza H, Boom WH, Hawn TR.mSystems. 2024 Aug 20:e0062824. doi: 10.1128/msystems.00628-24. Online ahead of print.PMID: 39162406

Declining number of general practitioners can impair influenza vaccination uptake among Italian older adults: Results from a panel analysis.

Domnich A, Lapi F, Orsi A, Grattagliano I, Rossi A, Cricelli C, Icardi G.BMC Health Serv Res. 2024 Aug 20;24(1):950. doi: 10.1186/s12913-024-11443-9.PMID: 39164724

Advice for when enzootic abortion vaccine is unavailable.

Henry J, Lovatt F.Vet Rec. 2024 Aug 17;195(4):158. doi: 10.1002/vetr.4627.PMID: 39150206

Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9-23 months old in Uganda, 2019-2020 - Preliminary report.

Casey RM, Najjengo MS, Lubega I, Sekiziyivu AB, Twinomuhwezi-Oyet E, Nakato WN, Sciarratta CN, Chu SY, Doshi RH, Kambugu A, Gidudu JF.Vaccine. 2024 Aug 15;42(22):126197. doi: 10.1016/j.vaccine.2024.126197. Online ahead of print.PMID: 39153293

The Human Monkeypox Virus and Host Immunity: Emerging Diagnostic and Therapeutic Challenges.

Singh V, Dwivedi S, Agrawal R, Sadashiv, Fatima G, Abidi A.Infect Disord Drug Targets. 2024 Aug 16. doi: 10.2174/0118715265309361240806064619. Online ahead of print.PMID: 39161149

Bioinformatic elucidation of conserved epitopes to design a potential vaccine candidate against existing and emerging SARS-CoV-2 variants of concern.

Rastogi A, Gautam S, Kumar M.Heliyon. 2024 Jul 23;10(15):e35129. doi: 10.1016/j.heliyon.2024.e35129. eCollection 2024 Aug 15.PMID: 39157328

Bibliometric analysis of dendritic cell-based vaccines over the past 15 years.

Long Z, Wu Y, Zhong L, Lu J, Liu B.Hum Vaccin Immunother. 2024 Dec 31;20(1):2392961. doi: 10.1080/21645515.2024.2392961. Epub 2024 Aug 19.PMID: 39161160

Identifying patterns and profiles of vaccination hesitancy among nurses for tailoring healthcare policies in the UK: A cross-sectional study.

Erfani G, McCready J, Nichol B, Gordon C, Unsworth J, Croston M, Comparcini D, Simonetti V, Cicolini G, Mikkonen K, Keisala J, Tomietto M.Int Nurs Rev. 2024 Aug 19. doi: 10.1111/inr.13035. Online ahead of print.PMID: 39158159

XBB.1.16-RBD-based trimeric protein vaccine can effectively inhibit XBB.1.16-included XBB subvariant infection.

Peng D, He C, Chen Z, Lei H, Huang X, Ye C, Wang B, Hao Y, Du X, Lu S, Hu H, Cheng W, Dong H, Lei J, Zhou X, Song X, Lu G, Wei X.MedComm (2020). 2024 Aug 16;5(9):e687. doi: 10.1002/mco2.687. eCollection 2024 Sep.PMID: 39156763

Interleukin-17B in common carp (Cyprinus carpio L.): Molecular cloning and immune effects as immune adjuvant of Aeromonas veronii formalin-killed vaccine.

Jiang X, Gao M, Ding Y, Wang J, Song Y, Xiao H, Kong X.Fish Shellfish Immunol. 2024 Aug 13:109832. doi: 10.1016/j.fsi.2024.109832. Online ahead of print.PMID: 39147176

Factors associated with human papillomavirus, hepatitis A, hepatitis B and mpox vaccination uptake among gay, bisexual and other men who have sex with men in the UK- findings from the large community-based RiiSH-Mpox survey.

Baldry G, Phillips D, Wilkie R, Checchi M, Folkard K, Simmons R, Saunders J, Mandal S, Mercer CH, Mohammed H, Ogaz D.Int J STD AIDS. 2024 Aug 20:9564624241273778. doi: 10.1177/09564624241273778. Online ahead of print.PMID: 39163149

Low-Dose Mildronate-Derived Lipidoids for Efficient mRNA Vaccine Delivery with Minimal Inflammation Side Effects.

Liu J, Xiao B, Yang Y, Jiang Y, Wang R, Wei Q, Pan Y, Chen Y, Wang H, Fan J, Li R, Xu H, Piao Y, Xiang J, Shao S, Zhou Z, Shen Y, Sun W, Tang J.ACS Nano. 2024 Aug 16. doi: 10.1021/acsnano.4c06160. Online ahead of print.PMID: 39151414

Improved RSV PreF protein vaccine quality and stability by elucidation of supercooling-induced aggregation phenomena.

Ju Cui T, Beugeling M, Kaserer W, van Heugten AJP, Capelle MAH.Eur J Pharm Biopharm. 2024 Aug 14:114457. doi: 10.1016/j.ejpb.2024.114457. Online ahead of print.PMID: 39151707

Zinc(ii)-mediated stereoselective construction of 1,2-*cis* 2-azido-2-deoxy glycosidic linkage: assembly of *Acinetobacter baumannii* K48 capsular pentasaccharide derivative.

Zhao X, Ding H, Guo A, Zhong X, Zhou S, Wang G, Liu Y, Ishiwata A, Tanaka K, Cai H, Liu XW, Ding F.Chem Sci. 2024 Jul 16;15(32):12889-12899. doi: 10.1039/d4sc03449j. eCollection 2024 Aug 14.PMID: 39148796

Regional differences in provider recommendation of HPV vaccines among 13-to-17 year old adolescents from 2019 to 2021.

Lynette Ejezie C, Cuccaro P, Savas LS, Shegog R.Vaccine. 2024 Aug 13;42(20):125974. doi: 10.1016/j.vaccine.2024.05.022. Epub 2024 May 24.PMID: 38796327

The promising prospects of a new yellow fever vaccine.

Roukens AHE, Visser LG.Lancet Infect Dis. 2024 Aug 14:S1473-3099(24)00487-0. doi: 10.1016/S1473-3099(24)00487-0. Online ahead of print.PMID: 39153487

Emerging Norovirus GII.12 infection in 2010 in Northern Taiwan.

Tsai CN, Chang YC, Chao HC, Hsu YH, Wang YH, Chen SY.J Formos Med Assoc. 2024 Aug 17:S0929-6646(24)00344-9. doi: 10.1016/j.jfma.2024.07.024. Online ahead of print.PMID: 39155177

Neutralizing antibodies against KP.2 and KP.3: why the current vaccine needs an update.

Gillot C, David C, Dogné JM, Cabo J, Douxfils J, Favresse J.Clin Chem Lab Med. 2024 Aug 16. doi: 10.1515/cclm-2024-0919. Online ahead of print.PMID: 39147380

Ubiquitination of NS1 Confers Differential Adaptation of Zika Virus in Mammalian Hosts and Mosquito Vectors.

Huang C, Jiang T, Pan W, Feng T, Zhou X, Wu Q, Ma F, Dai J.Adv Sci (Weinh). 2024 Aug 19:e2408024. doi: 10.1002/advs.202408024. Online ahead of print.PMID: 39159062

Identification of mutations in viral proteins involved in cell adaptation using a reverse genetic system of the live attenuated hepatitis A virus vaccine H2 strain.

Yan XL, Li J, Ma QQ, Wang HJ, Li L, Zhao H, Qin CF, Li XF.Virol Sin. 2024 Aug 14:S1995-820X(24)00131-7. doi: 10.1016/j.virs.2024.08.004. Online ahead of print.PMID: 39151705

National trends and disparities in herpes zoster vaccination among U.S. older adults with chronic obstructive pulmonary disease, 2008-2022.

Hung CT, Wang LM, Suk CW.Am J Infect Control. 2024 Aug 15:S0196-6553(24)00657-6. doi: 10.1016/j.ajic.2024.08.010. Online ahead of print.PMID: 39153516

The Healthcare Study Examines the Humoral Anti-S1 Antibody Response Following mRNA Vaccination, Comparing Individuals with and without Prior SARS-CoV-2 Infection.

Staruszkiewicz M, Pituch-Noworolska A, Skayne M, Matthias T, Skoczen S.Arch Immunol Ther Exp (Warsz). 2024 Aug 15;72(1). doi: 10.2478/aite-2024-0016. eCollection 2024 Jan 1.PMID: 39146978

Is Constrictive Pericarditis Associated with Long COVID, Its Vaccine, or Both?

Kaya Ç, Yalta K.Balkan Med J. 2024 Aug 19. doi: 10.4274/balkanmedj.galenos.2024.2024-6-109. Online ahead of print.PMID: 39155763

Fatty aldehyde bisulfite adducts as a purification handle in ionizable lipid synthesis.

Atwood G, Purbiya S, Reid C, Smith B, Kaur K, Wicks D, Gaudet P, MacLeod KC, Vincent-Rocan JF.RSC Adv. 2024 Aug 19;14(36):26233-26238. doi: 10.1039/d4ra05189k. eCollection 2024 Aug 16.PMID: 39161429

Fluorescence immunochromatographic detection of antibodies to the p72 protein of African swine fever virus.

Liu H, Chen W, Zhang Y, Chen Y, Zhou J, Liu E, Dai S, Wang A.Int J Biol Macromol. 2024 Aug 17:134852. doi: 10.1016/j.ijbiomac.2024.134852. Online ahead of print.PMID: 39159796

Enhanced oxidative stability of deuterated squalene: the impact of labelling extent on chemical resilience.

Möller J, Recsei C, Russell R, Darwish T.RSC Adv. 2024 Aug 19;14(36):26002-26006. doi: 10.1039/d4ra05543h. eCollection 2024 Aug 16.PMID: 39161447

Non-human primate model of long-COVID identifies immune associates of hyperglycemia.

Palmer CS, Perdios C, Abdel-Mohsen M, Mudd J, Datta PK, Maness NJ, Lehmicke G, Golden N, Hellmers L, Coyne C, Moore Green K, Midkiff C, Williams K, Tiburcio R, Fahlberg M, Boykin K, Kenway C, Russell-Lodrigue K, Birnbaum A, Bohm R, Blair R, Dufour JP, Fischer T, Saied AA, Rappaport J.Nat Commun. 2024 Aug 20;15(1):6664. doi: 10.1038/s41467-024-50339-4.PMID: 39164284

Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine.

Scholaert M, Peries M, Braun E, Martin J, Serhan N, Loste A, Bruner A, Basso L, Chaput B, Merle E, Descargues P, Pagès E, Gaudenzio N.Allergy. 2024 Aug 19. doi: 10.1111/all.16273. Online ahead of print.PMID: 39157907

Potential Biases in Test-Negative Design Studies of COVID-19 Vaccine Effectiveness Arising from the Inclusion of Asymptomatic Individuals.

Ortiz-Brizuela E, Carabali M, Jiang C, Merckx J, Talbot D, Schnitzer ME.Am J Epidemiol. 2024 Aug 19:kwae288. doi: 10.1093/aje/kwae288. Online ahead of print.PMID: 39160637

COVID-19 throughout pandemic waves and virus variants: a real-life experience in an Italian hospital.

Dettori S, Brucci G, Portunato F, Ponzano M, Magnasco L, Mirabella M, Magnè F, Delfino E, Balletto E, Sepulcri C, Vena A, Giacobbe DR, Marelli C, Ball L, Mikulska M, Di Biagio A, Bruzzone B, Signori A, Mora S, Giacomini M, Dentone C, Bassetti M.J Chemother. 2024 Aug 19:1-9. doi: 10.1080/1120009X.2024.2384321. Online ahead of print.PMID: 39161053

Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach.

Weskamm LM, Tarnow P, Harms C, Huchon M, Raadsen MP, Friedrich M, Rübenacker L, Grüttner C, Garcia MG; MVA-MERS-S-CEF study group; Koch T, Becker S, Sutter G, Lhomme E, Haagmans BL, Fathi A, Blois

SM, Dahlke C, Richert L, Addo MM.iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470. eCollection 2024 Aug 16.PMID: 39148710

Zap the clap with DNA: a novel microbicide for preventing *Neisseria gonorrhoeae* infection.

Rendon MA, So M.Antimicrob Agents Chemother. 2024 Aug 16:e0079424. doi: 10.1128/aac.00794-24. Online ahead of print.PMID: 39150247

A novel mRNA multi-epitope vaccine of Acinetobacter baumannii based on multi-target protein design in immunoinformatic approach.

Xu Y, Zhu F, Zhou Z, Ma S, Zhang P, Tan C, Luo Y, Qin R, Chen J, Pan P.BMC Genomics. 2024 Aug 19;25(1):791. doi: 10.1186/s12864-024-10691-7.PMID: 39160492

Opt-out vaccination in school and daycare: Reconciling parental authority and obligations.

Andersen DB, Pedersen VML.Bioethics. 2024 Aug 19. doi: 10.1111/bioe.13344. Online ahead of print.PMID: 39158110

Intradermal vaccination with a phytoglycogen nanoparticle and STING agonist induces cytotoxic T lymphocyte-mediated antitumor immunity.

Hernandez-Franco JF, Jan IM, Elzey BD, HogenEsch H.NPJ Vaccines. 2024 Aug 17;9(1):149. doi: 10.1038/s41541-024-00943-8.PMID: 39152131

Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia.

Chen Z, Gou Q, Yuan Y, Zhang X, Zhao Z, Liao J, Zeng X, Jing H, Jiang S, Zhang W, Zeng H, Huang W, Zou Q, Zhang J.Vaccine. 2024 Aug 19;42(23):126217. doi: 10.1016/j.vaccine.2024.126217. Online ahead of print.PMID: 39163713

"REAl LIfe" observational study on the effectiveness of Evusheld prophylaxis against SARS-CoV-2 omicron variants in vaccine non-responder immunocompromised patients (REALISE).

Esposito GL, Fassio F, Girardi D, Picasso E, Meloni F, Montini S, Codullo V, Pattonieri EF, Defrancesco I, Bianchessi A, Calvi M, Seminari EM, Baldanti F, Lilleri D, Novelli V, Marena C.Vaccine. 2024 Aug 17;42(23):126208. doi: 10.1016/j.vaccine.2024.126208. Online ahead of print.PMID: 39154513

Protocol for analyzing BCG-induced trained immunity in murine bone marrow-derived macrophages.

Xu JC, Hu Z, Fan XY.STAR Protoc. 2024 Aug 17;5(3):103267. doi: 10.1016/j.xpro.2024.103267. Online ahead of print.PMID: 39154346

Respiratory Syncytial Virus (RSV) Vaccine Uptake Among Older Adults: a Population-Based Study of Massachusetts Towns.

Gaffney A, Himmelstein DU, McCormick D, Woolhandler S.J Gen Intern Med. 2024 Aug 16. doi: 10.1007/s11606-024-08999-x. Online ahead of print.PMID: 39152348

BCG vaccination alters the epigenetic landscape of progenitor cells in human bone marrow to influence innate immune responses.

Sun SJ, Aguirre-Gamboa R, de Bree LCJ, Sanz J, Dumaine A, van der Velden WJFM, Joosten LAB, Khader S, Divangahi M, Netea MG, Barreiro LB.Immunity. 2024 Aug 14:S1074-7613(24)00370-4. doi: 10.1016/j.immuni.2024.07.021. Online ahead of print.PMID: 39153479

Correction: Vaccine Hesitancy in Taiwan: Temporal, Multilayer Network Study of Echo Chambers Shaped by Influential Users.

Yin JD.Online J Public Health Inform. 2024 Aug 15;16:e65413. doi: 10.2196/65413.PMID: 39146531

Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1β Secretion and T Cell Adjuvanticity.

Weiss AM, Lopez MA 2nd, Rosenberger MG, Kim JY, Shen J, Chen Q, Ung T, Ibeh UM, Knight HR, Rutledge NS, Studnitzer B, Rowan SJ, Esser-Kahn AP.J Med Chem. 2024 Aug 20. doi: 10.1021/acs.jmedchem.4c00516. Online ahead of print.PMID: 39162654

Notes from the Field: Heightened Precautions for Imported Dogs Vaccinated with Potentially Ineffective Rabies Vaccine - United States, August 2021-April 2024.

Freedman MS, Swisher SD, Wallace RM, Laughlin ME, Brown CM, Pieracci EG.MMWR Morb Mortal Wkly Rep. 2024 Aug 15;73(32):706-707. doi: 10.15585/mmwr.mm7332a3.PMID: 39146308

CD4⁺ T cells exhibit distinct transcriptional phenotypes in the lymph nodes and blood following mRNA vaccination in humans.

Borcherding N, Kim W, Quinn M, Han F, Zhou JQ, Sturtz AJ, Schmitz AJ, Lei T, Schattgen SA, Klebert MK, Suessen T, Middleton WD, Goss CW, Liu C, Crawford JC, Thomas PG, Teefey SA, Presti RM, O'Halloran JA, Turner JS, Ellebedy AH, Mudd PA.Nat Immunol. 2024 Aug 20. doi: 10.1038/s41590-024-01888-9. Online ahead of print.PMID: 39164479

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([13.08.2024 TO 20.08.2024]) *as the publication date 52 records.*

1.20240269259RABIES VIRUS VACCINE

US - 15.08.2024

Clasificación Internacional A61K 39/205Nº de solicitud 18643377Solicitante Intervet Inc.Inventor/a Ian Tarpey

The present invention provides a vaccine for rabies virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

2.4412709NEMATODENIMPFSTOFF

EP - 14.08.2024

Clasificación Internacional A61P 33/10Nº de solicitud 22878045Solicitante AGRESEARCH LTDInventor/a UMAIR SALEH

The present invention is directed to a vaccine comprising recombinant antigens derived from the parasitic nematode *Haemonchus contortus*, which will raise an immune response in farmed and wild ruminants that are susceptible or predisposed to infection by one or more nematode worm species. The recombinant antigens used in the invention are conserved among species of nematode worms so that the vaccine will provide protection against multiple types of nematode worms. In particular, the invention provides a composition or vaccine composition comprising the recombinant *H. contortus* antigens: (i) enolase (EN); (ii) arginine kinase (AK); and (iii) ornithine decarboxylase (ODC), or antigenic fragments thereof, together with a veterinary acceptable carrier or diluent.

3.WO/2024/164611ATOMIZED VACCINE INHALATION APPARATUS

WO - 15.08.2024

Clasificación Internacional A61M 11/00Nº de solicitud PCT/CN2023/131442Solicitante QINGDAO FUTURE MEDICAL TECHNOLOGY CO., LTD.Inventor/a WANG, Weilai

An atomized vaccine inhalation apparatus, wherein an atomized vaccine inhalation cup comprises a cup lid and a cup body (2). The cup lid is fastened to an upper end of the cup body (2), and the cup lid is provided with an inhalation port and an aerosol inlet (1.1, 4.1). The aerosol inlet (1.1, 4.1) is used for the insertion of an aerosol outlet (3.1) of an atomizer medicine cup (3). The inhalation port is used for inoculation, by oral inhalation or nasal inhalation, using an atomized vaccine that enters the cup body (2). The cup lid comprises an oral cup lid (1) or/and a nasal inhalation cup lid (4). The inhalation port on the oral cup lid (1) is an oral inhalation port (1.2), and the inhalation port on the nasal inhalation cup lid (4) is a nasal cavity inhalation port (4.2). The present invention can be used in conjunction with an atomizer to satisfy use scenarios of oral or/and nasal inhalation inoculation of atomized vaccines. The present invention further comprises an automatic cup dropper (5). The lower half of the automatic cup dropper (5) is cylindrically tube-shaped and has a bottom surface that has an open structure, the upper half is a semi-open cylindrical tube-shaped structure having a closed top, and the inner diameter of the cylindrical tube shape is smaller than the outer diameter of a cup mouth of the cup body. The automatic cup dropper (5) occupies a small space and has the characteristics of facilitating the transport, storage, picking up, and use of the atomized vaccine inhalation cup.

4.20240269271GLYCOPROTEIN D VARIANTS AS VACCINE ADJUVANTS

US - 15.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud 18407567Solicitante VIRION THERAPEUTICS, LLCInventor/a Hildegund CJ Ertl

Disclosed herein are compositions for increasing the immunogenicity of a vaccine antigen and methods of inducing an immune response in a subject using the compositions described herein. Disclosed herein are compositions for a therapeutic vaccine to HPV-associated cancers and methods of inducing an immune response to HPV in a subject using the compositions described herein.

5.12060389ENTEROVIRUS MULTI-ANTIGEN EPITOPE FUSION PROTEIN, GENE, VACCINE, AND PREPARATION METHOD THEREOF

US - 13.08.2024

Clasificación Internacional C07K 14/005Nº de solicitud 18412485Solicitante Institute of Medical Biology, Chinese Academy of Medical SciencesInventor/a Longding Liu

An enterovirus multi-antigen epitope fusion protein, a gene, a vaccine and a preparation method thereof are provided, relating to the field of vaccine preparation technologies. The amino acid sequence of the enterovirus multi-antigen epitope fusion protein is shown in SEQ ID NO: 4. The vaccine is prepared by adopting the preparation method of a genetically engineered protein vaccine, and the prepared vaccine has stronger specificity. After protein purification, there are fewer impure proteins and more specific antigen proteins, thus improving the effectiveness and safety of the combined vaccine.

6.20240269272VACCINE COMPOSITION COMPRISING ENCODED ADJUVANT

US - 15.08.2024

Clasificación Internacional A61K 39/39Nº de solicitud 18566077Solicitante NOUSCOM AGInventor/a Elisa SCARSELLI

The present invention relates to a vaccine composition comprising (1) a first set of one or more vectors comprising a nucleic acid encoding one or more adjuvants, wherein the first set of one or more vectors are adenoviral vectors, and (2) an antigen or a combination of antigens or a nucleic acid encoding said antigen or combination of antigens or a second set of one or more vectors comprising said nucleic acid. The invention further relates to said vaccine composition for use in the treatment or prophylaxis of a disease. In addition, the invention relates to a vaccine composition or vaccine kit for inducing an immune response comprising (1) a first nucleic acid encoding one or more adjuvants or a first set of one or more vectors comprising said first nucleic acid and (2) an antigen or a combination of antigens or a second nucleic acid encoding said second antigen or combination of antigens or a second set of one or more vectors comprising said second nucleic acid, wherein (1) is administered to a patient at a first location and (2) is administered to the patient at a second location, wherein the first location is the same or within 20 cm of the second location and the lymphatic system of the first and second location drains to the same lymph nodes. The invention also relates to a vaccination regimen comprising a first administration step comprising administration of an antigen and an encoded adjuvant, and a second administration step comprising administration of an antigen and/or an encoded adjuvant.

7.WO/2024/168224ENGINEERED NIPAH VIRUS MRNA VACCINE

WO - 15.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/015123Solicitante VERNAGEN, LLCInventor/a KIM, Baek

Provided herein are a Nipah virus vaccine composition including (i) a messenger ribonucleic acid (mRNA) including an open reading frame (ORF) encoding soluble Nipah virus glycoprotein (soluble NiV-G) fused with human collagen type I alpha 1 (COL1A1) signal peptide, (ii) a mRNA including an ORF encoding full-length Nipah virus glycoprotein (full-length NiV-G), (iii) a mRNA including an ORF encoding full-length Nipah virus fusion protein (full-length NiV-F), or (iv) the mRNA including the ORF encoding full-length NiV-G, and the mRNA including the ORF encoding full-length NiV-F, and a method of inducing immune response against Nipah virus by administering an effective amount of the Nipah virus vaccine composition to a subject in need thereof.

8.20240269255HPV INFECTIOUS DISEASE VACCINE

US - 15.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud 18561804Solicitante DAIICHI SANKYO COMPANY, LIMITEDInventor/a Yoshikuni ONODERA

Provided are lipid particles encapsulating a nucleic acid capable of expressing an E6 antigen and an E7 antigen of human papillomavirus, whereby a vaccine for preventing and/or treating infection with human papillomavirus type 6 and/or type 11 can be provided. The lipid particles comprise a lipid that is a cationic lipid having the general formula (Ia), or a pharmaceutically acceptable salt thereof.

[In the formula, R^1, R^2, p, L^1 and L^2 are as defined in the specification.]

9.20240269266BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

US - 15.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18601925Solicitante THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventor/a Lbachir BenMohamed

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

10.20240269171EPSTEIN-BARR VIRUS (EBV) ANTIGEN COMPOSITES AND DENDRITIC CELL (DC)-BASED VACCINE, AND USE THEREOF

US - 15.08.2024

Clasificación Internacional A61K 35/15Nº de solicitud 18574764Solicitante Helen LIUInventor/a Helen LIU

Epstein-Barr virus (EBV) antigen composites and a dendritic cell (DC)-based vaccine, and a use thereof in preparation of a drug for controlling an EBV-associated infectious disease are provided. Patient-derived DCs are stimulated in vitro, loaded with lysates of various types of EBV-infected cells with strong immunogenicity for EBV-associated infectious diseases, and induced into mature dendritic cells (mDCs) by various cytokines and specific agonists, so as to obtain a complete DC-based vaccine with corresponding antigens. The DC-based vaccine can be injected back into the patient to activate the immune system to produce cytotoxic T cells, thereby killing EBV-infected cells, exerting an immunological effect, and improving a life quality of the patient. In addition, the DC-based vaccine can be prepared in about one week with a low cost, is safe, and shows no obvious side effects.

11.WO/2024/164391HEAT-RESISTANT PROTECTIVE AGENT FOR SWINE ERYSIPELAS LIVE VACCINE, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 15.08.2024

Clasificación Internacional A61K 47/42Nº de solicitud PCT/CN2023/081576Solicitante JINYUBAOLING BIO-PHARMACEUTICAL CO., LTDInventor/a LI, Chao

A heat-resistant protective agent for a swine erysipelas live vaccine, a preparation method therefor, and a use thereof. The heat-resistant protective agent comprises the following components in mass/volume percent: 8% to 12% of maltodextrin, 3% to 5% of gelatin, 1% to 2% of L-arginine hydrochloride, 1% to 3% of polyvinylpyrrolidone, 1% to 3% of L-histidine hydrochloride, 6% to 8% of enzyme-hydrolyzed casein, 3% to 5% of D-sorbitol, 1% to 2% of sodium thiosulfate, 3% to 6% of tert-butyl alcohol, and 1% to 3% of polyethyleneimine, the remainder being water for injection. According to the heat-resistant protective agent, a swine erysipelas live vaccine can be stably stored for a long time, the decrease in the titer of live bacteria in the swine erysipelas live vaccine is inhibited, immune efficacy is ensured, and the swine erysipelas live vaccine also has a good freeze-dried appearance, a relatively low water content and good dissolution characteristics.

12.20240269257INORGANIC POLYATOMIC OXYANIONS FOR PROTECTING AGAINST ANTIGENIC DAMAGE DURING PATHOGEN INACTIVATION FOR VACCINE PRODUCTION

US - 15.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18500970Solicitante Najít Technologies, Inc.Inventor/a Ian J. Amanna

Provided are methods for rapidly inactivating a pathogen, or for producing a vaccine composition containing an inactivated noninfectious pathogen having retained antigenicity and/or immunogenicity, comprising exposing the pathogen to a chemical inactivating agent (e.g., one or more chemical oxidizing, alkylating or crosslinking agents) in the presence of inorganic polyatomic oxyanions in an amount and for a time sufficient to render the pathogen noninfectious while enhancing retention of pathogen antigenicity and/or immunogenicity relative to that retained by contacting the pathogen with the chemical inactivating agent alone. The methods are broadly applicable to pathogens having RNA or DNA genomes (e.g., including viruses, bacteria, fungi, and parasites). Also provided are vaccine compositions (medicaments) containing a pathogen inactivated by exposure to an inactivating agent in the presence of elevated concentrations of inorganic polyatomic oxyanions, and methods for eliciting an immune response in a subject by administering the vaccine compositions.

13.WO/2024/168177AFRICAN SWINE FEVER VIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME

WO - 15.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/015039Solicitante KANSAS STATE UNIVERSITY RESEARCH FOUNDATIONInventor/a SHI, Jishu

A safe and efficacious live-attenuated vaccine is presented, (LAV) VNUA-ASFV-LAVL2, generated by serial passaging of a field isolate (VNUA-ASFV-05L1, genotype II) in porcine alveolar macrophage (PAMs, 65 passages) and an immortalized porcine alveolar macrophage cell line (3D4/21, 55 passages). VNUA-ASFV-

LAVL2 can efficiently replicate in both PAMs and 3D4/21 cells. It provides 100% protection, even with the low dose of 10^2 HAD_{50}, for the vaccinated pigs against the challenge of contemporary pandemic ASFV field isolate. Pigs vaccinated with this LAV at a dose range of 10^2 to 10^5 HAD_{50} remain clinically healthy during both an observation period of immunization and a 28-day observation period of challenge. VNUA-ASFV-LAVL2 is eliminated from blood by 28 days post inoculation (DPI, and from feces or oral fluids by 17 DPI. ASFV-specific IgG antibodies and significant cellular immunity can be detected in vaccinated pigs before an ASFV challenge.

14.20240269262METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES

US - 15.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18286025Solicitante University of Florida Research Foundation, IncorporatedInventor/a Duane Mitchell

The invention provides methods of making vaccines against viruses, including against SARS-Cov-2. Such methods entail identifying areas of a viral genome that are highly conserved and making vaccines that target the highly conserved areas. The invention provides a polypeptide vaccine comprising a SARS-Cov-2 polypeptide or an immunogenic fragment thereof and a pharmaceutically acceptable excipient. The invention provides a polynucleotide vaccine comprising a polynucleotide encoding a SARS-Cov-2 polypeptide or immunogenic fragment thereof linked to a heterologous promoter and a pharmaceutically acceptable excipient. The invention provides methods for effecting prophylaxis of or treating SARS-Cov-2 infection comprising a step of administering a polypeptide vaccine and/or a polynucleotide vaccine to a subject in need thereof.

15.20240269263IMMUNOMODULATORY COMPOSITIONS AND RELATED METHODS

US - 15.08.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18433923Solicitante Flagship Pioneering Innovations VII, LLCInventor/a Ellen Lovisa Larsdotter AFZELIUS

Provided herein are, inter alia, compositions (e.g., vaccine compositions (e.g., vaccine booster compositions)) comprising a hIL-10R binding agent (e.g., a hIL-10R binding protein (or a nucleic acid molecule comprising the same)) and optionally an immunogen (e.g., an immunogenic protein (or a nucleic acid molecule encoding the same)). Further provided herein are methods of utilizing hIL-10R binding agents (e.g., hIL-10R binding proteins (or nucleic acid molecules comprising the same)), including, e.g., in methods of vaccination, e.g., as vaccine boosters.

16.WO/2024/167885IMMUNOMODULATORY COMPOSITIONS AND RELATED METHODS

WO - 15.08.2024

Clasificación Internacional C07K 14/44Nº de solicitud PCT/US2024/014558Solicitante FLAGSHIP PIONEERING INNOVATIONS VII, LLCInventor/a AFZELIUS, Ellen Lovisa Larsdotter

Provided herein are, *inter alia*, compositions (*e.g.,* vaccine compositions (*e.g.,* vaccine booster compositions)) comprising a hIL-10R binding agent (*e.g.,* a hIL-10R binding protein (or a nucleic acid molecule comprising the same)) and optionally an immunogen (*e.g.,* an immunogenic protein (or a nucleic acid molecule encoding the same)). Further provided herein are methods of utilizing hIL-10R binding agents (*e.g.,* hIL-10R binding

proteins (or nucleic acid molecules comprising the same)), including, *e.g.*, in methods of vaccination, *e.g.*, as vaccine boosters.

17.4412647MULTIVALENTE INFLUENZAIMPFSTOFFE

EP - 14.08.2024

Clasificación Internacional A61K 39/12Nº de solicitud 22801613Solicitante SANOFI PASTEUR INCInventor/a ALEFANTIS TIMOTHY

Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.

18.20240269258MULTIVALENT INFLUENZA VACCINES

US - 15.08.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18627824Solicitante SANOFI PASTEUR INC.Inventor/a Timothy ALEFANTIS

Disclosed are multivalent vaccine or immunogenic compositions comprising influenza virus hemagglutinin (HA) from standard of care influenza virus strains, or ribonucleic acid molecules encoding the same; and one or more influenza virus HA identified or designed by machine learning, or one or more ribonucleic acid molecules that encode the influenza virus HA identified or designed by machine learning. Also disclosed are methods of using the vaccine or immunogenic compositions.

19.20240270829VACCINE THERAPY

US - 15.08.2024

Clasificación Internacional C07K 16/18Nº de solicitud 18395150Solicitante AC Immune SAInventor/a Andrea Pfeifer

The present invention provides means for treating, alleviating and preventing amyloid-related pathology in young to middle-aged subjects with Down's syndrome (DS). In particular, the present invention provides antigenic peptide fragments derived from amyloid protein or amyloid-like protein for use in the preventive treatment of amyloid-related pathology in young to middle-aged subjects with Down's syndrome.

20.4413033VERFAHREN ZUR BESTIMMUNG NOROVIRUSREAKTIVER ANTIKÖRPER

EP - 14.08.2024

Clasificación Internacional C07K 16/10Nº de solicitud 22800964Solicitante TAKEDA VACCINES INCInventor/a BRAUN RALPH

The present disclosure is directed to methods for determining the presence and/or amount of norovirus-reactive antibodies in a sample from a subject. The subject may be vaccinated with a norovirus vaccine or infected with a norovirus. The present disclosure further relates to *in vitro* methods for diagnosing a norovirus infection and determining protection against a norovirus infection in a subject for instance after vaccination with a norovirus vaccine. The present disclosure is further directed to kits for determining norovirus-reactive

antibodies in a sample. The present disclosure is further directed to microsphere complexes comprising microspheres coupled to norovirus virus like particles.

21.WO/2024/167669COMBINATIONS OF DENDRITIC CELL-BASED VACCINES AND CHECKPOINT INHIBITORS

WO - 15.08.2024

Clasificación Internacional A61K 35/15Nº de solicitud PCT/US2024/012603Solicitante MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor/a KNUTSON, Keith, L.

Methods and materials for treating cancer (e.g., ovarian cancer) using a combination of a Th 17 DC vaccine and an immune checkpoint inhibitor are provided herein.

22.WO/2024/168014DENDRITIC CELL-BASED VACCINES AND USES THEREOF

WO - 15.08.2024

Clasificación Internacional A61K 35/15Nº de solicitud PCT/US2024/014767Solicitante MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventor/a KNUTSON, Keith L.

Methods and materials for treating cancer (e.g., ovarian cancer) using a combination of a Th17 DC vaccine, optionally in combination with an immune checkpoint inhibitor, are provided herein.

23.WO/2024/167803ADJUVANT FORMULATIONS INCLUDING LOW VISCOSITY CHITOSAN OR CHITOSAN DERIVATIVES

WO - 15.08.2024

Clasificación Internacional A61K 47/36Nº de solicitud PCT/US2024/014372Solicitante MERCK SHARP & DOHME LLCInventor/a STRABLE, Erica L.

The invention relates generally to the use of chitosan and chitosan derivatives as an adjuvant in a vaccine composition. More specifically, the invention relates to pharmaceutical compositions and formulations that include a low viscosity chitosan or a trimethyl chitosan.

24.20240269269SELF-ASSEMBLING NANOPARTICLES

US - 15.08.2024

Clasificación Internacional A61K 39/385Nº de solicitud 18494491Solicitante Barinthus Biotherapeutics North America, Inc.Inventor/a Geoffrey Martin Lynn

The present disclosure relates to a vaccine comprising at least one peptide antigen conjugate having the formula selected from PEG-[E1]-A-[E2]-[U]—H and H—[U]-[E1]-A-[E2]-PEG, wherein E1 is an N terminal extension, E2 is a C terminal extension, A is peptide antigen, H is hydrobhobic block, wherein one or more drug molecules (D) are optionally attached to each H directly or via a suitable linker X1; U is a linker, [ ] denotes the group is optional and - denotes that the two adjacent groups are directly attached to one another by a covalent bond or indirectly to one another via a suitable linker X. The vaccine is useful in treating or preventing a cancer, an autoimmune disease, an allergy, or an infectious disease.

25.2024205414CANINE LYME DISEASE VACCINE

AU - 15.08.2024

Clasificación Internacional Nº de solicitud 2024205414Solicitante Intervet International B.V.Inventor/a CALLISTER, Steven M

26.4413144RNA-IMPFSTOFF-LIPIDNANOPARTIKEL

EP - 14.08.2024

Clasificación Internacional C12N 15/85Nº de solicitud 22878062Solicitante GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULCInventor/a GEALL ANDY JOHN

Disclosed are recombinant expression vectors useful as RNA vaccines. Also disclosed are pharmaceutically acceptable carriers for the recombinant expression vectors, particularly lipid nanoparticles.

27.WO/2024/167071NOVEL LOW-TEMPERATURE-ADAPTIVE ATTENUATED MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS

WO - 15.08.2024

Clasificación Internacional C12N 7/00Nº de solicitud PCT/KR2023/008704Solicitante PIONEERVACCINE INC.Inventor/a SEO, Heejeong

The present invention relates to a novel low-temperature-adaptive attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) and uses thereof, in which, by stepwise adapting a MERS-CoV to low temperatures, a novel low-temperature-adaptive attenuated MERS-CoV that enables effective prevention of MERS-CoV infection was developed, and can be useful as a vaccine and therapeutic agent able to prevent Middle East respiratory syndrome.

28.20240269267SYNTHETIC DNA VACCINE IMMUNOGENIC IMPROVEMENTS

US - 15.08.2024

Clasificación Internacional A61K 39/295Nº de solicitud 18566859Solicitante The Wistar Institute of Anatomy and BiologyInventor/a David Weiner

Disclosed herein is a composition comprising one or more viral antigen or a recombinant nucleic acid sequence that encodes one or more viral antigen with enhanced immunogenicity in vivo. Also disclosed herein is a method of generating an immune response in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating a viral infection in a subject using said composition and methods.

29.20240269640METHODS AND COMPOSITIONS FOR LARGE-SCALE CONJUGATABLE POLYMER AND PROTEIN SYNTHESIS

US - 15.08.2024

Clasificación Internacional B01J 19/00Nº de solicitud 18496770Solicitante Ligandal, Inc.Inventor/a Andre Watson

Methods and compositions for manufacturing large-scale quantities of conjugatable peptides/peptoids/polymers/nucleic acids and conjugatable proteins, as well as hybrid materials consisting of synthetic and unnatural amino acids, glycopeptides, proteoglycans, and other molecular modifications are disclosed, for a variety of purposes including rapid antidote and vaccine applications in biodefense,

therapeutics, diagnostics, theranostics, thin films, multilayered assemblies, biofilms, sensors, drug delivery vehicles, gene delivery vehicles, gene editing vehicles, staged release compounds, and the like.

30.4413021SPEZIFISCHE BACULOVIRUS-HAUPTHÜLLGLYKOPROTEIN-GP64-BINDENDE PROTEINE

EP - 14.08.2024

Clasificación Internacional C07K 14/31Nº de solicitud 22802032Solicitante NAVIGO PROTEINS GMBHInventor/a FIEDLER ERIK

gp64 is the major envelope glycoprotein of baculoviruses. The present invention relates to novel proteins that specifically bind to the baculovirus envelope protein gp64. The novel proteins of the present invention are advanced and powerful tools because they allow precise capturing of gp64 in affinity chromatography. The gp64 binding proteins are particularly useful tools within the process of protein production (e.g. vaccine production) to provide for gp64 free samples. Further, the binding protein for gp64 are useful for methods to analyze the presence of gp64.

31.20240269252COMPOSITIONS FOR INDUCING AN IMMUNE RESPONSE

US - 15.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 18544197Solicitante President and Fellows of Harvard CollegeInventor/a Nisarg J. Shah

Acute myeloid leukemia (AML) is a clonal disorder of hematopoietic stem and progenitor cells. It is a devastating disease with a poor prognosis and an average 5-year survival rate of about 30%. Disclosed herein are composition and methods for treating leukemia with a biomaterial comprising a polymer scaffold, a dendritic cell activating factor, a dendritic cell recruitment factor, and at least one leukemia antigen. The biomaterial-based vaccine disclosed herein promotes a potent, durable and transferable immune response against acute myeloid leukemia to prevent cell engraftment and synergizes with chemotherapy to prevent relapse.

32.WO/2024/165898AUTOMATED DIGITAL INJECTION GUN WITH THE ABILITY TO STORE THE INJECTION DATA OF EACH LIVESTOCK.

WO - 15.08.2024

Clasificación Internacional A61M 5/145Nº de solicitud PCT/IB2023/053871Solicitante MOHAMMADIOUNOTIKANDI, AliInventor/a MOHAMMADIOUNOTIKANDI, Ali

An animal injection gun with a comprehensive system of drug and vaccine injection for domestic and wild animals, which, in addition to performing hard injections, stores comprehensive and complete information on the proportion of each animal in the system so that if needed, this information can be used from the birth of the new baby to the end of the animal's life and prevented the spread of herd diseases. The components of this device include: the electronic circuit controlling the engine, the part which functions for injection, the placement location of the carpules, battery, controlling lights, needle head, push button, battery, storage location of injection data and other parts of the device has been embedded on the gun.

33.20240271147TOBAMOVIRUS PSEUDOVIRIONS FOR STABILISING SINGLE STRANDED RNA

US - 15.08.2024

Clasificación Internacional C12N 15/82Nº de solicitud 18568456Solicitante University of Cape TownInventor/a Ann Elizabeth MEYERS

Provided herein is a method for stabilising a single stranded RNA (ssRNA) by encapsidation of the ssRNA with a tobamovirus coat protein to obtain a pseudovirion (PsV), the method comprising expressing a tobamovirus coat protein and the ssRNA comprising a tobamovirus encapsidation origin (OriA), wherein the expressed tobamovirus coat protein interacts with the OriA sequence on the ssRNA to initiate encapsidation of the ssRNA by the tobamovirus coat protein, thereby forming a pseudovirion. The PsVs produced according to the method can be used as a diagnostic control composition, where the ssRNA is a sequence detected by a molecular diagnostic assay. The pseudovirions may also be used as a vaccine to elicit an immune response in a subject, and in pharmaceutical compositions to be administered to a subject.

34.WO/2024/167866MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

WO - 15.08.2024

Clasificación Internacional C07K 14/075Nº de solicitud PCT/US2024/014505Solicitante CYANVAC LLCInventor/a HE, Biao

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

35.20240272143RELEASE ASSAY FOR DETERMINING POTENCY OF SELF-AMPLIFYING RNA DRUG PRODUCT AND METHODS FOR USING

US - 15.08.2024

Clasificación Internacional C12Q 1/6804Nº de solicitud 18567056Solicitante GLAXOSMITHKLINE BIOLOGICALS SAInventor/a Qiongman KONG

A potency release assay for measuring the potency of drug product composition comprising self-amplifying mRNA (SAM) that encodes at least one immunogenic polypeptide or at least one therapeutic peptide and a non-viral delivery system is described. In one embodiment the drug product is a vaccine comprising SAM and a non-viral delivery system such as SAM/lipid nanoparticle (LNP) delivery system, a Cationic Nanoemulsion (CNE) delivery system, or another SAM delivery system. It is demonstrated that the potency of a SAM drug product can be assessed in an in vitro system, at the RNA amplification stage (agnostic assay), by measuring the amount of double-stranded RNA (dsRNA) in cells which have been transfected with the SAM in the drug product. Thus, dsRNA can be used as a surrogate endpoint for potency. It is demonstrated that there is a very high correlation between total dsRNA in a cell culture transfected with the SAM and the potency of the SAM based drug product.

36.20240270796VACCINE COMPOSITIONS OF HERPESVIRUS ENVELOPE PROTEIN COMBINATIONS TO INDUCE IMMUNE RESPONSE

US - 15.08.2024

Clasificación Internacional C07K 14/005Nº de solicitud 18494219Solicitante THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.Inventor/a Xinle Cui

Provided are antigenic compositions and uses thereof that include at least two human herpesvirus (HHV) polypeptides involved in mediating HHV binding, fusion, and entry into host cells, such as gp350, gH, gL, and gB, or nucleic acids encoding the polypeptides. The two HHV polypeptides comprise any combination of: a gB polypeptide; a gp350 polypeptide; a gL polypeptide; and a gH polypeptide, and optionally any one or more of the following polypeptides: gp42, gM, gN, gl, gC, gE, gD, ORF68, BMRF-2, BDLF2, UL128, UL130, UL131A, and gpK8.1. Also disclosed are methods of inducing an immune response or treating or preventing O an HHV infection in a subject by administering to the subject at least two of the HHV polypeptides or nucleic acid(s) encoding the same. Methods of passively transferring immunity using high-titer anti-HHV antibodies or immune cells are also disclosed.

37.WO/2024/165753COLD STORAGE DEVICE

WO - 15.08.2024

Clasificación Internacional F25D 3/08Nº de solicitud PCT/EP2024/053372Solicitante B MEDICAL SYSTEMS S.À R.LInventor/a PIRES, Daniel

An ice-lined cold storage device, notably a vaccine storage device, is provided with an indication of simulated autonomy indicating the duration during which a payload will be maintained below a pre-specified temperature without use of a cooling circuit to remove energy from the cold storage device. The simulated autonomy is provided using a temperature model which uses data which is specific to the ice-lined cold storage device and by: a) detecting an initial ambient temperature, an initial storage compartment temperature and an initial ice-lining temperature of the ice-lined cold storage device; b) running a first simulation using the temperature model and using the initial ambient temperature, the initial storage compartment temperature and the initial ice-lining temperature to determine a first simulated storage compartment temperature after a first simulation time step; c) running one or more subsequent simulations, each subsequent simulation being run using the temperature model and using data created in a previous simulation, to determine a subsequent simulated storage compartment temperature after a subsequent simulation time step; and d) determining the simulated autonomy of the ice-lined refrigerator using at least one of the subsequent simulated storage compartment temperature(s).

38.20240269260MRNA-BASED VACCINE COMPOSITION FOR INDUCING IMMUNE RESPONSE AGAINST HIV AND HPV

US - 15.08.2024

Clasificación Internacional A61K 39/21Nº de solicitud 18501992Solicitante Sarfaraz K. NiaziInventor/a Sarfaraz K. Niazi

The present invention generally relates to the field of molecular biology and immunology; more specifically, the invention relates to a messenger RNA (mRNA) composition to express selected epitopes of the antigens of Human Immunodeficiency Virus (HIV) and Human Papillomavirus (HPV) for inducing an immune response to prevent or treat HIV and HPV infections.

39.20240269253DNA VACCINE FOR USE IN THE THERAPEUTIC AND/OR PROPHYLACTIC TREATMENT OF TUMOR DISEASES

US - 15.08.2024

Clasificación Internacional A61K 39/00Nº de solicitud 18695235Solicitante UNIVERSITA' DEGLI STUDI DI TORINOInventor/a Francesco NOVELLI

A recombinant expression vector suitable for eliciting an immune response a subject having a tumor is provided. In addition to a promoter and additional transcription regulatory elements, the recombinant expression vector has a nucleotide sequence coding for an immunogenic synthetic peptide of SEQ ID NO:15.

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES

CUBA